

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 02/059321 A2

(51) International Patent Classification⁷: **C12N 15/40**,
15/51, 5/10, C07K 14/18, C12N 15/85

Pomezia (Rome) (IT). **MIGLIACCIO, Giovanni** [IT/IT];
IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia (Rome)
(IT). **PAONESSA, Giacomo** [IT/IT]; IRBM, Via Pontina
Km. 30, 600, I-00040 Pomezia (Rome) (IT).

(21) International Application Number: PCT/EP02/00526

(22) International Filing Date: 16 January 2002 (16.01.2002)

(74) Agent: **THOMPSON, John**; Merck & Co., Inc., European
Patent Department, Terlings Park, Eastwick Road, Harlow,
Essex CM20 2QR (GB).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): CA, JP, US.

(30) Priority Data:
60/263,479 23 January 2001 (23.01.2001) US

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(71) Applicant (*for all designated States except US*): **ISTI-
TUTO DI RICERCHE DI BIOLOGIA MOLECO-
LARE P. ANGELETTI SPA** [IT/IT]; Via Pontina Km.
30, 600, I-00040 Pomezia (Rome) (IT).

Published:

— *without international search report and to be republished
upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DE FRANCESCO,
Raffaele** [IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 02/059321 A2

(54) Title: HEPATITIS C VIRUS REPLICONS AND REPLICON ENHANCED CELLS

(57) Abstract: The present invention features nucleic acid containing one or more adaptive mutations, and HCV replicon enhanced cells. Adaptive mutations are mutations that enhance HCV replicon activity. HCV replicon enhanced cells are cells having an increased ability to maintain an HCV replicon.

TITLE OF THE INVENTION

HEPATITIS C VIRUS REPLICONS AND REPLICON ENHANCED CELLS

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 The present application claims priority to U.S. Serial No. 60/263,479, filed January 23, 2001, hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

- 10 The references cited in the present application are not admitted to be prior art to the claimed invention.

- It is estimated that about 3% of the world's population are infected with the Hepatitis C virus (HCV). (Wasley, *et al.*, 2000. *Semin. Liver Dis.* 20, 1-16.) Exposure to HCV results in an overt acute disease in a small percentage of cases, while in most instances the virus establishes a chronic infection causing liver
15 inflammation and slowly progresses into liver failure and cirrhosis. (Iwarson, 1994. *FEMS Microbiol. Rev.* 14, 201-204.) In addition, epidemiological surveys indicate an important role of HCV in the pathogenesis of hepatocellular carcinoma. (Kew, 1994. *FEMS Microbiol. Rev.* 14, 211-220, Alter, 1995. *Blood* 85, 1681-1695.)

- The HCV genome consists of a single strand RNA of about 9.5 kb in
20 length, encoding a precursor polyprotein of about 3000 amino acids. (Choo, *et al.*, 1989. *Science* 244, 362-364, Choo, *et al.*, 1989. *Science* 244, 359-362, Takamizawa, *et al.*, 1991. *J. Virol.* 65, 1105-1113.) The HCV polyprotein contains the viral proteins in the order: C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B.

- Individual viral proteins are produced by proteolysis of the HCV
25 polyprotein. Host cell proteases release the putative structural proteins C, E1, E2, and p7, and create the N-terminus of NS2 at amino acid 810. (Mizushima, *et al.*, 1994. *J. Virol.* 68, 2731-2734, Hijikata, *et al.*, 1993. *P.N.A.S. USA* 90, 10773-10777.)

- The non-structural proteins NS3, NS4A, NS4B, NS5A and NS5B
presumably form the virus replication machinery and are released from the
30 polyprotein. A zinc-dependent protease associated with NS2 and the N-terminus of NS3 is responsible for cleavage between NS2 and NS3. (Grakoui, *et al.*, 1993. *J. Virol.* 67, 1385-1395, Hijikata, *et al.*, 1993. *P.N.A.S. USA* 90, 10773-10777.) A distinct serine protease located in the N-terminal domain of NS3 is responsible for proteolytic cleavages at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B
35 junctions. (Barthenschlager, *et al.*, 1993. *J. Virol.* 67, 3835-3844, Grakoui, *et al.*,

1993. *Proc. Natl. Acad. Sci. USA* 90, 10583-10587, Tomei, *et al.*, 1993. *J. Virol.* 67, 4017-4026.) NS4A provides a cofactor for NS3 activity. (Failla, *et al.*, *J. Virol.* 1994. 68, 3753-3760, De Francesco, *et al.*, U.S. Patent No. 5,739,002.) NS5A is a highly phosphorylated protein concurring interferon resistance. (De Francesco, *et al.*, 2000. *Semin Liver Dis.*, 20(1), 69-83, Pawlotsky, 1999. *J. Viral Hepat. Suppl. 1*, 47-48.)
- 5 NS5B provides an RNA polymerase. (De Francesco, *et al.*, International Publication Number WO 96/37619, Behrens, *et al.*, 1996. *EMBO* 15, 12-22, Lohmann, *et al.*, 1998. *Virology* 249, 108-118.)
- Lohmann, *et al.*, *Science* 285, 110-113, 1999, illustrates the ability of a
- 10 biscistronic HCV replicon to replicate in a hepatoma cell line. The biscistronic HCV replicon contained a neomycin cistron and an NS2-NS5B or an NS3-NS5B cistron. "NS2-NS5B" refers to a NS2-NS3-NS4A-NS4B-NS5A-NS5B polyprotein. "NS3-NS5B" refers to a NS3-NS4A-NS4B-NS5A-NS5B polyprotein.
- Bartenschlager, European Patent Application 1 043 399, published
- 15 October 11, 2000 (not admitted to be prior art to the claimed invention), describes a cell culture system for autonomous HCV RNA replication and protein expression. Replication and protein expression is indicated to occur in sufficiently large amounts for quantitative determination. European Patent Application 1 043 399 indicates that prior cell lines or primary cell cultures infected with HCV do not provide favorable
- 20 circumstances for detecting HCV replication.

SUMMARY OF THE INVENTION

The present invention features nucleic acid containing one or more adaptive mutations, and HCV replicon enhanced cells. Adaptive mutations are

25 mutations that enhance HCV replicon activity. HCV replicon enhanced cells are cells having an increased ability to maintain an HCV replicon.

An HCV replicon is an RNA molecule able to autonomously replicate in a cultured cell and produce detectable levels of one or more HCV proteins. The basic subunit of an HCV replicon encodes for a HCV NS3-NS5B polyprotein along

30 with a suitable 5' UTR-partial core (PC) region and 3' UTR. The 5' UTR-PC region is made up of a 5'UTR region and about 36 nucleotides of the beginning of the core. Additional regions may be present including those coding for HCV proteins or elements such as the complete core, E1, E2, p7 or NS2; and those coding for other types of proteins or elements such as a encephalomyocarditis virus (EMCV) internal

35 ribosome entry site (IRES), a reporter protein or a selection protein.

The present application identifies different adaptive mutations that enhance HCV replicon activity. Enhancing replicon activity brings about at least one of the following: an increase in replicon maintenance in a cell, an increase in replicon replication, and an increase in replicon protein expression.

5 Adaptive mutations are described herein by identifying the location of the adaptive mutation with respect to a reference sequence present in a particular region. Based on the provided reference sequence, the same adaptive mutation can be produced in corresponding locations of equivalent regions having an amino acid sequence different than the reference sequence. Equivalent regions have the same
10 function or encode for a polypeptide having the same function.

 Replicon enhanced cells are a preferred host for the insertion and expression of an HCV replicon. Replicon enhanced cells are initially produced by creating a cell containing a HCV replicon and then curing the cell of the replicon. The term "replicon enhanced cell" includes cells cured of HCV replicons and progeny
15 of such cells.

 Thus, a first aspect of the present invention describes a nucleic acid molecule comprising at least one of the following regions: an altered NS3 encoding region, an altered NS5A encoding region, and an altered EMCV IRES region. The altered region contains one or more adaptive mutations. Reference to the presence of
20 particular adaptive mutation(s) does not exclude other mutations or adaptive mutations from being present. Adaptive mutations are described with reference to either an encoded amino acid sequence or a nucleic acid sequence.

 A nucleic acid molecule can be single-stranded or part of a double strand, and can be RNA or DNA. Depending upon the structure of the nucleic acid
25 molecule, the molecule may be used as a replicon or in the production of a replicon. For example, single-stranded RNA having the proper regions can be a replicon, while double-stranded DNA that includes the complement of a sequence coding for a replicon or replicon intermediate may be useful in the production of the replicon or replicon intermediate.

30 Preferred nucleic acid molecules are those containing region(s) from SEQ. ID. NOs. 1, 2, or 3, or the RNA version thereof, with one or more adaptive mutations. Reference to "the RNA version thereof" indicates a ribose backbone and the presence of uracil instead of thymine.

 The presence of a region containing an adaptive mutation indicates that
35 at least one such region is present. In different embodiments, for example, adaptive

mutations described herein are present at least in the NS3 region, in the NS5A region, in the NS3 and NS5A regions, in the EMCV IRES and NS3 regions, in the EMCV and NS5A regions, and in the ECMV IRES, NS3 and NS5A regions.

Another aspect of the present invention describes an expression vector
5 comprising a nucleotide sequence of an HCV replicon or replicon intermediate coupled to an exogenous promoter. Reference to a nucleotide sequence "coupled to an exogenous promoter" indicates the presence and positioning of an RNA promoter such that it can mediate transcription of the nucleotide sequence and that the promoter is not naturally associated with the nucleotide sequence being transcribed. The
10 expression vector can be used to produce RNA replicons.

Another aspect of the present invention describes a recombinant human hepatoma cell. Reference to a recombinant cell includes an initially produced cell and progeny thereof.

Another aspect of the present invention describes a method of making
15 a HCV replicon enhanced cell. The method involves the steps of: (a) introducing and maintaining an HCV replicon into a cell and (b) curing the cell of the HCV replicon.

Another aspect of the present invention describes an HCV replicon enhanced cell made by a process comprising the steps of: (a) introducing and maintaining an HCV replicon into a cell and (b) curing the cell of the HCV replicon.

20 Another aspect of the present invention describes a method of making a HCV replicon enhanced cell comprising an HCV replicon. The method involves (a) introducing and maintaining a first HCV replicon into a cell, (b) curing the cell of the replicon, and (c) introducing and maintaining a second replicon into the cured cell, where the second replicon may be the same or different as the first replicon.

25 Another aspect of the present invention describes an HCV replicon enhanced cell containing a HCV replicon made by the process involving the step of introducing an HCV replicon into an HCV replicon enhanced cell. The HCV replicon introduced into the HCV replicon enhanced cell may be the same or different than the HCV replicon used to produce the HCV replicon enhanced cell. In a preferred
30 embodiment, the HCV replicon introduced into an HCV replicon enhanced cell is the same replicon as was used to produce the enhanced cell.

Another aspect of the present invention describes a method of measuring the ability of a compound to affect HCV activity using an HCV replicon comprising an adaptive mutation described herein. The method involves providing a
35 compound to a cell comprising the HCV replicon and measuring the ability of the

compound to affect one or more replicon activities as a measure of the effect on HCV activity.

Another aspect of the present invention describes a method of measuring the ability of a compound to affect HCV activity using an HCV replicon enhanced cell that comprises an HCV replicon. The method involves providing a
5 compound to the cell and measuring the ability of the compound to effect one or more replicon activities as a measure of the effect on HCV activity.

Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples.
10 The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.

15 BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1G illustrate the nucleic acid sequence for the pHCVNeo.17 coding strand (SEQ. ID. NO. 3). The different regions of pHCVNeo.17 are provided as follows:

- 1-341: HCV 5' non-translated region, drives translation of the core-neo fusion protein;
- 20 342-1181: Core-neo fusion protein, selectable marker;
- 1190-1800: Internal ribosome entry site of the encephalomyocarditis virus, drives translation of the HCV NS region;
- 1801-7755: HCV polyprotein from non-structural protein 3 to non-structural protein 5B;
- 25 1801-3696: Non-structural protein 3 (NS3), HCV NS3 protease/helicase;
- 3697-3858: Non-structural protein 4A (NS4A), NS3 protease cofactor;
- 3859-4641: Non-structural protein 4B (NS4B);
- 4642-5982: Non-structural protein 5A (NS5A);
- 5983-7755: Non-structural protein 5B (NS5B); RNA-dependent RNA polymerase
- 30 7759-7989: HCV 3' non-translated region; and
- 7990-10690 plasmid sequences comprising origin of replication, beta lactamase coding sequence, and T7 promoter.

DETAILED DESCRIPTION OF THE INVENTION

HCV replicons and HCV replicon enhanced cells can be used to produce a cell culture providing detectable levels of HCV RNA and HCV protein. HCV replicons and HCV replicon enhanced hosts can both be obtained by selecting
5 for the ability to maintain an HCV replicon in a cell. As illustrated in the examples provided below, adaptive mutations present in HCV replicons and host cells can both assist replicon maintenance in a cell.

The detectable replication and expression of HCV RNA in a cell culture system has a variety of different uses including being used to study HCV
10 replication and expression, to study HCV and host cell interactions, to produce HCV RNA, to produce HCV proteins, and to provide a system for measuring the ability of a compound to modulate one or more HCV activities.

Preferred cells for use with a HCV replicon are Huh-7 cells and Huh-7 derived cells. "Huh-7 derived cells" are cell produced starting with Huh-7 cells and
15 introducing one or more phenotypic and/or genotypic modifications.

Adaptive Mutations

Adaptive mutations enhance the ability of an HCV replicon to be maintained and expressed in a host cell. Adaptive mutations can be initially selected
20 for using a wild type HCV RNA construct or a mutated HCV replicon. Initial selection involves providing HCV replicons to cells and identifying clones containing a replicon.

Nucleic acid sequences of identified HCV replicons can be determined using standard sequencing techniques. Comparing the sequence of input HCV
25 constructs and selected constructs provides the location of mutations. The effect of particular mutation(s) can be measured by, for example, producing a construct to contain particular mutation(s) and measuring the effect of these mutation(s). Suitable control constructs for comparison purposes include wild type constructs and constructs previously evaluated.

30 Adaptive mutations were predominantly found in the HCV NS3 and NS5A regions. With the exception of two silent mutations in NS5A and NS5B, consensus mutations occurring in the NS region resulted in changes to the deduced amino acid sequence. Noticeably, the amino acid changes occurred in residues that are conserved in all or a large number of natural HCV isolates. HCV sequences are
35 well known in the art and can be found, for example, in GenBank.

Adaptive mutations described herein can be identified with respect to a reference sequence. The reference sequence provides the location of the adaptive mutation in, for example, the NS3 or NS5A RNA, cDNA, or amino acid sequence. The remainder of the sequence encodes for a functional protein that may have the same, or a different, sequence than the reference sequence.

Preferred NS3 and NS5A adaptive mutations and examples of changes that can be made to produce such mutations are shown in Tables 1 and 2. The amino acid numbering shown in Tables 1 and 2 is with respect to SEQ. ID. NO. 1. The nucleotide numbering shown in Tables 1 and 2 is with respect to SEQ. ID. NO. 2. SEQ. ID. NO. 1 provides the amino acid sequence of the Con1 HCV isolate (Accession Number AJ238799). SEQ. ID. NO. 2 provides the nucleic acid sequence of the Con1 HCV isolate.

TABLE 1

15

Preferred NS3 Adaptive Mutations	
Amino Acid	Nucleotide
gly1095ala	G3625C
glu1202gly	A3946G
ala1347thr	G4380A

TABLE 2

Preferred NS5A Adaptive Mutations	
Amino Acid	Nucleotide
Lys@2039	AAA@6458
asn2041thr	A6463C
ser2173phe	C6859T
ser2197phe	C6931T
leu2198ser	T6934C
ala2199thr	G6936A
ser2204arg	C6953A (or G)

"@" refers to an addition.

Preferred adaptive mutations identified with respect to a reference sequence can be produced changing the encoding region of SEQ. ID. NO. 1, or an equivalent sequence, to result in the indicated change. Preferred adaptive mutations
 5 provided in Tables 1 and 2 occur in amino acids conserved among different HCV isolates.

Adaptive mutations have different effects. Some mutations alone, or in combination with other mutations, enhance HCV replicon activity. In some cases, two or more mutations led to synergistic effects and in one case, a slightly
 10 antagonistic effect was observed.

An adaptive mutation once identified can be introduced into a starting construct using standard genetic techniques. Examples of such techniques are provided by Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, and Sambrook, *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd Edition,
 15 Cold Spring Harbor Laboratory Press, 1989.

HCV replicons containing adaptive mutations can be built around an NS3 region or NS5A region containing one or more adaptive mutations described herein. The final replicon will contain replicon components needed for replication and may contain additional components.

20 SEQ. ID. NO. 2 can be used as a reference point for different HCV regions as follows:

5' UTR- nucleotides 1-341;
 Core- nucleotides 342-914;
 E1- nucleotides 915-1490;
 25 E2- nucleotides 1491-2579;
 P7- nucleotides 2580-2768;
 NS2- nucleotides 2769-3419;
 NS3- nucleotides 3420-5312;
 NS4A- nucleotides 5313-5474;
 30 NS4B- nucleotides 5475-6257;
 NS5A- nucleotides 6258-7598;
 NS5B- nucleotides 7599-9371; and
 3' UTR- nucleotides 9374-9605.

The amino acid sequences of the different structural and non-structural regions is
 35 provided by SEQ. ID. NO. 1.

Nucleic acid sequences encoding for a particular amino acid can be produced taking into account the degeneracy of the genetic code. The degeneracy of the genetic code arises because almost all amino acids are encoded for by different combinations of nucleotide triplets or "codons". The translation of a particular codon
 5 into a particular amino acid is well known in the art (*see, e.g., Lewin GENES IV, p. 119, Oxford University Press, 1990*). Amino acids are encoded for by RNA codons as follows:

- A=Ala=Alanine: codons GCA, GCC, GCG, GCU
- C=Cys=Cysteine: codons UGC, UGU
- 10 D=Asp=Aspartic acid: codons GAC, GAU
- E=Glu=Glutamic acid: codons GAA, GAG
- F=Phe=Phenylalanine: codons UUC, UUU
- G=Gly=Glycine: codons GGA, GGC, GGG, GGU
- H=His=Histidine: codons CAC, CAU
- 15 I=Ile=Isoleucine: codons AUA, AUC, AUU
- K=Lys=Lysine: codons AAA, AAG
- L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU
- M=Met=Methionine: codon AUG
- N=Asn=Asparagine: codons AAC, AAU
- 20 P=Pro=Proline: codons CCA, CCC, CCG, CCU
- Q=Gln=Glutamine: codons CAA, CAG
- R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU
- S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU
- T=Thr=Threonine: codons ACA, ACC, ACG, ACU
- 25 V=Val=Valine: codons GUA, GUC, GUG, GUU
- W=Trp=Tryptophan: codon UGG
- Y=Tyr=Tyrosine: codons UAC, UAU.

Constructs, including subgenomic and genomic replicons, containing one or more of the adaptive mutations described herein can also contain additional
 30 mutations. The additional mutations may be adaptive mutations and mutations not substantially inhibiting replicon activity. Mutations not substantially inhibiting replicon activity provide for a replicon that can be introduced into a cell and have detectable activity.

HCV Replicon

HCV replicons include the full length HCV genome and subgenomic constructs. A basic HCV replicon is a subgenomic construct containing an HCV 5' UTR- PC region, an HCV NS3-NS5B polyprotein encoding region, and a HCV 3' UTR. Other nucleic acid regions can be present such as those providing for HCV NS2, structural HCV protein(s) and non-HCV sequences.

The HCV 5' UTR-PC region provides an internal ribosome entry site (IRES) for protein translation and elements needed for replication. The HCV 5'UTR-PC region includes naturally occurring HCV 5' UTR extending about 36 nucleotides into a HCV core encoding region, and functional derivatives thereof. The 5'-UTR-PC region can be present in different locations such as site downstream from a sequence encoding a selection protein, a reporter, protein, or an HCV polyprotein.

Functional derivatives of the 5'-UTR-PC region able to initiate translation and assist replication can be designed taking into structural requirements for HCV translation initiation. (See, for example, Honda, *et al.*, 1996. *Virology* 222, 31-42). The affect of different modifications to a 5' UTR-PC region can be determined using techniques that measure replicon activity.

In addition to the HCV 5' UTR-PC region, non-HCV IRES elements can also be present in the replicon. The non-HCV IRES elements can be present in different locations including immediately upstream the region encoding for an HCV polyprotein. Examples of non-HCV IRES elements that can be used are the EMCV IRES, poliovirus IRES, and bovine viral diarrhea virus IRES.

The HCV 3' UTR assists HCV replication. HCV 3' UTR includes naturally occurring HCV 3' UTR and functional derivatives thereof. Naturally occurring 3' UTR's include a poly U tract and an additional region of about 100 nucleotides. (Tanaka, *et al.*, 1996. *J. Virol.* 70, 3307-3312, Kolykhalov, *et al.*, 1996. *J. Virol.* 70, 3363-3371.) At least *in vivo*, the 3' UTR appears to be essential for replication. (Kolykhalov, *et al.*, 2000. *J. Virol.* 2000 4, 2046-2051.) Examples of naturally occurring 3' UTR derivatives are described by Bartenschlager International Publication Number EP 1 043 399.

The NS3-NS5B polyprotein encoding region provides for a polyprotein that can be processed in a cell into different proteins. Suitable NS3-NS5B polyprotein sequences that may be part of a replicon include those present in different HCV strains and functional equivalents thereof resulting in the processing of NS3-NS5B to

a produce functional replication machinery. Proper processing can be measured for by assaying, for example, NS5B RNA dependent RNA polymerase.

The ability of an NS5B protein to provide RNA polymerase activity can be measured using techniques well known in the art. (See, for example, De
5 Francesco, *et al.*, International Publication Number WO 96/37619, Behrens, *et al.*, 1996. *EMBO* 15:12-22, Lohmann, *et al.*, 1998. *Virology* 249:108-118.) Preferably, the sequence of the active NS5B is substantially similar as that provided in SEQ. ID. NO. 1, or a wild type NS5B such as strains HCV-1, HCV-2, HCV-BK, HCV-J, HCV-N, HCV-H. A substantially similar sequence provides detectable HCV polymerase
10 activity and contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid alterations to that present in a HCV NS5B polymerase. Preferably, no more than 1, 2, 3, 4 or 5 alterations are present.

Alterations to an amino acid sequence provide for substitution(s), insertion(s), deletion(s) or a combination thereof. Sites of different alterations can be
15 designed taking into account the amino acid sequences of different NS5B polymerases to identify conserved and variable amino acid, and can be empirically determined.

HCV replicons can be produced in a wide variety of different cells and *in vitro*. Suitable cells allow for the transcription of a nucleic acid encoding for an HCV replicon.
20

Additional Sequences

An HCV replicon may contain non-HCV sequences in addition to HCV sequences. The additional sequences should not prevent replication and expression, and preferably serve a useful function. Sequences that can be used to
25 serve a useful function include a selection sequence, a reporter sequence, transcription elements and translation elements.

Selection Sequence

A selection sequence in an HCV replicon facilitates the identification
30 of a cell containing the replicon. Selection sequences are typically used in conjunction with some selective pressure that inhibits growth of cells not containing the selection sequence. Examples of selection sequences include sequences encoding for antibiotic resistance and ribozymes.

Antibiotic resistance can be used in conjunction with an antibiotic to
35 select for cells containing replicons. Examples of selection sequences providing for

antibiotic resistance are sequences encoding resistance to neomycin, hygromycin, puromycin, or zeocin.

A ribozyme serving as a selection sequence can be used in conjunction with an inhibitory nucleic acid molecule that prevents cellular growth. The ribozyme
5 recognizes and cleaves the inhibitory nucleic acid.

Reporter Sequence

A reporter sequence can be used to detect replicon replication or protein expression. Preferred reporter proteins are enzymatic proteins whose presence
10 can be detected by measuring product produced by the protein. Examples of reporter proteins include, luciferase, beta-lactamase, secretory alkaline phosphatase, beta-glucuronidase, green fluorescent protein and its derivatives. In addition, a reporter nucleic acid sequence can be used to provide a reference sequence that can be targeted by a complementary nucleic acid. Hybridization of the complementary nucleic acid to
15 its target can be determined using standard techniques.

Additional Sequence Configuration

Additional non-HCV sequences are preferable 5' or 3' of an HCV replicon genome or subgenomic genome region. However, the additional sequences
20 can be located within an HCV genome as long as the sequences do not prevent detectable replicon activity. If desired, additional sequences can be separated from the replicon by using a ribozyme recognition sequence in conjunction with a ribozyme.

Additional sequences can be part of the same cistron as the HCV polypeptide or can be a separate cistron. If part of the same cistron, the selection or
25 reporter sequence coding for a protein should result in a product that is either active as a chimeric protein or is cleaved inside a cell so it is separated from HCV protein.

Selection and reporter sequences encoding for a protein when present as a separate cistron should be associated with elements needed for translation. Such
30 elements include a 5' IRES.

Detection Methods

Methods for detecting replicon activity include those measuring the production or activity of replicon RNA and encoded for protein. Measuring includes
35 qualitative and quantitative analysis.

Techniques suitable for measuring RNA production include those detecting the presence or activity of RNA. The presence of RNA can be detected using, for example, complementary hybridization probes or quantitative PCR. Techniques for measuring hybridization between complementary nucleic acid and quantitative PCR are well known in the art. (See for example, Ausubel, *Current Protocols in Molecular Biology*, John Wiley, 1987-1998, Sambrook, *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and U.S. Patent No. 5,731,148.)

RNA enzymatic activity can be provided to the replicon by using a ribozyme sequence. Ribozyme activity can be measured using techniques detecting the ability of the ribozyme to cleave a target sequence.

Techniques for measuring protein production include those detecting the presence or activity of a produced protein. The presence of a particular protein can be determined by, for example, immunological techniques. Protein activity can be measured based on the activity of an HCV protein or a reporter protein sequence.

Techniques for measuring HCV protein activity vary depending upon the protein that is measured. Techniques for measuring the activity of different non-structural proteins such as NS2/3, NS3, and NS5B, are well known in the art. (See, for example, references provided in the Background of the Invention.)

Assays measuring replicon activity also include those detecting virion production from a replicon that produces a virion; and those detecting a cytopathic effect from a replicon producing proteins exerting such an effect. Cytopathic effects can be detected by assays suitable to measure cell viability.

Assays measuring replicon activity can be used to evaluate the ability of a compound to modulate HCV activities. Such assays can be carried out by providing one or more test compounds to a cell expressing an HCV replicon and measuring the effect of the compound on replicon activity. If a preparation containing more than one compound is found to modulate replicon activity, individual compounds or smaller groups of compounds can be tested to identify replicon active compounds.

Compounds identified as inhibiting HCV activity can be used to produce replicon enhanced cells and may be therapeutic compounds. The ability of a compound to serve as a therapeutic compound can be confirmed using animal models such as a chimpanzee to measure efficacy and toxicity.

Replicon Enhanced Host Cell

Replicon enhanced cells are initially produced by selecting for a cell able to maintain an HCV replicon and then curing the cell of the replicon. Cells produced in this fashion were found to have an increased ability to maintain a replicon upon subsequent HCV replicon transfection.

Initial transfection can be performed using a wild-type replicon or a replicon containing one or more adaptive mutations. If a wild-type replicon is employed, the replicon should contain a selection sequence to facilitate replicon maintenance.

Cells can be cured of replicons using different techniques such as those employing replicon inhibitory agent. In addition, replication of HCV replicons is substantially reduced in confluent cells. Thus, it is conceivable to cure cells of replicons by culturing them at a high density.

Replicon inhibitory agents inhibit replicon activity or select against a cell containing a replicon. An example of such an agent is IFN- α . Other HCV inhibitory compounds may also be employed. HCV inhibitor compounds are described, for example, in Llinas-Brunet, *et al.*, 2000. *Bioorg Med Chem. Lett.* 10(20), 2267-2270.

The ability of a cured cell to be a replicon enhanced cell can be measured by introducing a replicon into the cell and determining efficiency of subsequent replicon maintenance and activity.

EXAMPLES

Examples are provided below to further illustrate different features of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.

Example 1: Techniques

This example illustrates the techniques employed for producing and analyzing adaptive mutations and replicon enhanced cells.

Manipulation of Nucleic Acids and Construction of Recombinant Plasmids

Manipulation of nucleic acids was done according to standard protocols. (Sambrook, *et al.*, 1989. *Molecular Cloning: A Laboratory Manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.) Plasmid DNA was

prepared from ON culture in LB broth using Qiagen 500 columns according to manufacturer instructions.

Plasmids containing desired mutations were constructed by restriction digestion using restriction sites flanking the mutations or by PCR amplification of the area of interest, using synthetic oligonucleotides with the appropriate sequence. Site directed mutagenesis was carried out by inserting the mutations in the PCR primers. PCR amplification was performed using high fidelity thermostable polymerases or mixtures of polymerases containing a proofreading enzyme. (Barnes, *et al.*, 1994. *Proc. Natl. Acad. Sci.* 91, 2216-2220.) All plasmids were verified by restriction mapping and sequencing.

pHCVneo17.wt contains the cDNA for an HCV bicistronic replicon identical to replicon I₃₇₇neo/NS3-3'/wt described by Bartenschlager (SEQ. ID. NO. 3) (Lohmann, *et al.*, 1999. *Science* 285,110-113, EMBL-genbank No. AJ242652). The plasmid comprises the following elements: 5' untranslated region of HCV comprising the HCV-IRES and part of the core (nt1-377); neomycin phosphotransferase coding sequence; and EMCV IRES; HCV coding sequences from NS3 to NS5B; 3' UTR of HCV.

Plasmid pHCVNeo17.GAA is identical to pHCVNeo.17, except that the GAC triplets (nt. 6934-6939 of pHCVNeo17 sequence) coding for the catalytic aspartates of the NS5B polymerase (amino acids 2737 and 2738 of HCV polyprotein) were changed into GCG, coding for alanine.

Plasmid pHCVNeo17.m0 is identical to pHCVNeo17, except that the triplet AGC (nt. 5335-5337 of pHCVNeo17 sequence) coding for the serine of NS5A protein (amino acid 2204 of HCV polyprotein) was changed into AGA, coding for arginine.

Plasmid pHCVNeo17.m1 is identical to pHCVNeo17, except that the triplet AAC (nt. 4846-4848 of pHCVNeo17 sequence) coding for the asparagine of NS5A protein (amino acid 2041 of HCV polyprotein) was changed into ACC, coding for threonine.

Plasmid pHCVNeo17.m2 is identical to pHCVNeo17, except that the triplet TCC (nt. 5242-5244 of pHCVNeo17 sequence) coding for the serine of NS5A protein (amino acid 2173 of HCV polyprotein) was changed into TTC, coding for phenylalanine.

Plasmid pHCVNeo17.m3 is identical to pHCVNeo17, except that the triplet TCC (nt. 5314-5316 of pHCVNeo17 sequence) coding for the serine of NS5A protein (amino acid 2197 of HCV polyprotein) was changed into TTC, coding for phenylalanine.

- 5 Plasmid pHCVNeo17.m4 is identical to pHCVNeo17, except that the triplet TTG (nt. 5317-5319 of pHCVNeo17 sequence) coding for the leucine of NS5A protein (amino acid 2198 of HCV polyprotein) was changed into TCG, coding for serine.

- 10 Plasmid pHCVNeo17.m5 is identical to pHCVNeo17, except that an extra triplet AAA coding for lysine was inserted after the triplet GTG (nt. 4840-4843 of pHCVNeo17 sequence), coding for valine 2039 of HCV polyprotein.

- 15 Plasmid pHCVNeo17.m6 is identical to pHCVNeo17, except that the triplets GAA and GCC (nt. 2329-2331 and 2764-2766 of pHCVNeo17 sequence) coding for the glutamic acid and the alanine of NS3 protein (amino acid 1202 and 1347 of HCV polyprotein) were changed respectively into GGA and ACC, coding for glycine and threonine. The triplet TCC (nt. 5242-5244 of pHCVNeo17 sequence) coding for the serine of NS5A protein (amino acid 2173 of HCV polyprotein) was changed into TTC, coding for phenylalanine; an extra adenosine was inserted into the EMCV IRES (after the thymidine 1736 of the replicon sequence).

- 20 Plasmid pHCVNeo17.m7 is identical to pHCVNeo17, except that the triplet AAC (nt. 4846-4848 of pHCVNeo17 sequence) coding for the asparagine of NS5A protein (amino acid 2041 of HCV polyprotein) was changed into ACC, coding for threonine; the triplet TCC (nt. 5242-5244 of pHCVNeo17 sequence) coding for the serine of NS5A protein (amino acid 2173 of HCV polyprotein) was changed into
25 TTC, coding for phenylalanine.

- Plasmid pHCVNeo17.m8 is identical to pHCVNeo17, except that the triplet AAC (nt. 4846-4848 of pHCVNeo17 sequence) coding for the asparagine of NS5A protein (amino acid 2041 of HCV polyprotein) was changed into ACC, coding for threonine; the triplet TCC (nt. 5314-5316 of pHCVNeo17 sequence) coding for
30 the serine of NS5A protein (amino acid 2197 of HCV polyprotein) was changed into TTC, coding for phenylalanine.

Plasmid pHCVNeo17.m9 is identical to pHCVNeo17, except that the triplet AAC (nt. 4846-4848 of pHCVNeo17 sequence) coding for the asparagine of NS5A protein (amino acid 2041 of HCV polyprotein) was changed into ACC, coding

for threonine; the triplet TTG (nt. 5317-5319 of pHCVNeo17 sequence) coding for the leucine of NS5A protein (amino acid 2198 of HCV polyprotein) was changed into TCG, coding for serine.

5 Plasmid pHCVNeo17.m10 is identical to pHCVNeo17, except that the triplet GAA (nt. 2329-2331 of pHCVNeo17 sequence) coding for the glutamic acid of NS3 protein (amino acid 1202 of HCV polyprotein) was changed into GGA, coding for glycine; an extra triplet AAA coding for lysine was inserted after the triplet GTG (nt. 4840-4843 of pHCVNeo17 sequence), coding for valine 2039 of HCV polyprotein.

10 Plasmid pHCVNeo17.m11 is identical to pHCVNeo17, except that the triplet TCC (nt. 5314-5316 of pHCVNeo17 sequence) coding for the serine of NS5A protein (amino acid 2197 of HCV polyprotein) was changed into TTC, coding for phenylalanine. The triplet GCC (nt. 5320-5322 of pHCVNeo17 sequence) coding for the alanine of NS5A protein (amino acid 2199 of HCV polyprotein) was changed into
15 ACC coding for threonine.

Plasmid pHCVNeo17.m12 is identical to pHCVNeo17, except that the triplet AAC (nt. 4846-4848 of pHCVNeo17 sequence) coding for the asparagine of NS5A protein (amino acid 2041 of HCV polyprotein) was changed into ACC, coding for threonine; the triplet TCC (nt. 5314-5316 of pHCVNeo17 sequence) coding for
20 the serine of NS5A protein (amino acid 2197 of HCV polyprotein) was changed into TTC, coding for phenylalanine. The triplet GCC (nt. 5320-5322 of pHCVNeo17 sequence) coding for the alanine of NS5A protein (amino acid 2199 of HCV polyprotein) was changed into ACC coding for threonine.

Plasmid pHCVNeo17.m13 has the same mutations as
25 pHCVNeo17.m8, but also an extra adenosine inserted into the EMCV IRES (after the thymidine 1736 of the replicon sequence).

Plasmid pHCVNeo17.m14 has the same mutations as pHCVNeo17.m11, but also an extra adenosine inserted into the EMCV IRES (after the thymidine 1736 of the replicon sequence).

30 Plasmid pHCVNeo17.m15 is identical to pHCVNeo17, except that the triplet GCC (nt. 5320-5322 of pHCVNeo17 sequence) coding for the alanine of NS5A protein (amino acid 2199 of HCV polyprotein) was changed into ACC coding for threonine.

Plasmid pRBSEAP.5 is a pHCVNeo.17 derivative where the Neo coding sequence has been replaced with the sequence coding for the human placental alkaline phosphatase corresponding to nucleotides 90-1580 of pBC12/RSV/SEAP plasmid. (Berger, *et al.*, 1988. *Gene* 66, 1-10.)

5

RNA Transfection

Transfection was performed using Huh-7 cells. The cells were grown in Dulbecco's modified minimal essential medium (DMEM, Gibco, BRL) supplemented with 10% FCS. For routine work, cells were passed 1 to 5 twice a week using 1x trypsin/EDTA (Gibco, BRL).

10

Plasmids were digested with the ScaI endonuclease (New England Biolabs) and transcribed *in vitro* with the T7 Megascript kit (Ambion). Transcription mixtures were treated with DNase I (0.1 U/ml) for 30 minutes at 37°C to completely remove template DNA, extracted according to the procedure of Chomczynski (Chomczynski, *et al.*, 1987. *Anal. Biochem.* 162, 156-159), and resuspended with RNase-free phosphate buffered saline (rfPBS, Sambrook, *et al.*, 1989. *Molecular Cloning: A Laboratory Manual*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).

15

RNA transfection was performed as described by Liljestrom, *et al.*, 1991. *J. Virol.* 6, 4107-4113, with minor modifications. Subconfluent, actively growing cells were detached from the tissue culture container using trypsin/EDTA. Trypsin was neutralised by addition of 3 to 10 volumes of DMEM/10%FCS and cells were centrifuged for 5 minutes at 1200 rpm in a Haereus table top centrifuge at 4°C. Cells were resuspended with ice cold rfPBS by gentle pipetting, counted with a haemocytometer, and centrifuged as above. rfPBS wash was repeated once and cells were resuspended at a concentration of $1-2 \times 10^7$ cell/ml in rfPBS. Aliquots of cell suspension were mixed with RNA in sterile eppendorf tubes. The RNA/cell mixture was immediately transferred into the electroporation cuvette (precooled on ice) and pulsed twice with a gene pulser apparatus equipped with pulse controller (Biorad). Depending on the experiment, 0.1, 0.2 or 0.4 cm electrode gap cuvettes were used, and settings adjusted (Table 3).

25

30

TABLE 3

Cuvette	Volume	Voltage	Capacitance	Resistance	RNA
gap (cm)	(μ l)	(Volts)	(μ Fa)	(ohm)	(μ g)
0.1	70	200	25	infinite	1-10
0.2	200	400	25	infinite	5-20
0.4	800	800	25	infinite	15-100

After the electric shock, cells were left at room temperature for 1-10 minutes (essentially the time required to electroporate all samples) and subsequently diluted with at least 20 volumes of DMEM/10%FCS and plated as required for the experiment. Survival and transfection efficiency were monitored by measuring the neutral red uptake of cell cultured for various days in the absence or in the presence of neomycin sulfate (G418). With these parameters, survival of Huh-7 cells was usually 40-60% and transfection efficiency ranged between 40% and 100%.

Sequence Analysis of Replicon RNAs

The entire NS region was recloned from 3 different transfection experiments performed with HCVNeo.17 RNA. RNA was extracted from selected clones either using the Qiagen RNAeasy minikit following manufacturer instructions or as described by Chomczynski, *et al.*, 1987. Anal. Biochem. 162, 156-159.

Replicon RNAs (5 μ g of total cellular RNA) were retro-transcribed using oligonucleotide HCVG34 (5'- ACATGATCTGCAGAGAGGCCAGT-3'; SEQ. ID. No. 4) and the Superscript II reverse transcriptase (Gibco, BRL) according to manufacturer instructions, and subsequently digested with 2 U/ml Ribonuclease H (Gibco BRL). The cDNA regions spanning from the EMCV IRES to the HCV 3' end were amplified by PCR using oligonucleotides HCVG39 (5'- GACASGCTGTGATAWATGTCTCCCCC-3'; SEQ. ID. NO. 5) and CITE3 (5'- TGGCTCTCCTCAAGCGTATTC -3'; SEQ. ID. NO. 6) and the LA Taq DNA polymerase (Takara LA Taq).

Amplified cDNAs were digested with the KpnI endonuclease (New England Biolabs) and the 5.8 kb fragments were gel purified and ligated to the 5.6 kb vector fragment (purified from plasmid pRBSEAP.5 digested with KpnI) using T4

DNA ligase (New England Biolabs) according to manufacturer instructions. Ligated DNAs were transformed by electroporation in DH10B or JM119 strains of *E. coli*.

In the case of NS5A region, total RNA isolated from 3 clones, (HB77, HB60 and HB68) was extracted and used for RT-PCR. 5µg of total RNA plus 20 pmole of AS61 oligo (5'-ACTCTCTGCAGTCAAGCGGCTCA-3', RT antisense oligo; SEQ. ID. NO. 7) were heated 5 minutes at 95°C, then DMSO (5% f.c.), DTT (10 mM f.c.), 1 mM dNTP (1 mM f.c.), 1x Superscript buffer (1 x f.c.), and 10 u Superscript (Gibco) were added to a total volume of 20 µl and incubated 3 hours at 42°C. 2µl of this RT reaction were used to perform PCR with oligos S39 (5'-CAGTGGATGAACCGGCTGATA-3', sense; SEQ. ID. NO. 8) or S41 (5'-GGGGCGACGGCATCATGCAAACC-3', sense; SEQ. ID. NO. 9) and B43 (5'-CAGGACCTGCAGTCTGTCAAAGG-3', antisense; SEQ. ID. NO. 10) using Elongase Enzyme Mix (Gibco) according the instruction provided by the manufacturer. The resulting PCR fragment was cloned in pCR2.1 vector using the TA Cloning kit (Invitrogen) and transformed in Top10F' bacterial strain.

Plasmid DNA was prepared from ON culture of the resulting ampicillin resistant colonies using Qiagen 500 columns according to manufacturer instructions. The presence of the desired DNA insert was ascertained by restriction digestion, and the nucleotide sequence of each plasmid was determined by automated sequencing. Nucleotide sequences and deduced amino acids sequences were aligned using the GCG software.

TaqMan

TaqMan analysis was typically performed using 10 ng of RNA in a reaction mix (TaqMan Gold RT-PCR kit, Perkin Elmer Biosystems) either with HCV specific oligos/probe (oligo 1: 5'-CGGGAGAGCCATAGTGG-3'; SEQ. ID. NO. 11, oligo 2: 5'-AGTACCACAAGGCCTTTTCG-3'; SEQ. ID. NO. 12, probe: 5'-CTGCGGAACCGGTGAGTACAC-3'; SEQ. ID. NO. 13) or with human GAPDH specific oligos/probe (Pre-Developed TaqMan Assay Reagents, Endogenous Control Human GAPDH, Part Number 4310884E, Perkin Elmer Biosystems). PCR was performed using a Perkin Elmer ABI PRISM 7700 under the following conditions: 30 minutes at 48°C (the RT step), 10 minutes at 95°C and 40 cycles: 15 seconds at 95°C and 1 minute at 60°C. Quantitative calculations were obtained using the Comparative C_T Method (described in User Bulletin #2, ABI PRISM 7700 Sequence Detection System, Applied Biosystem, Dec 1997) considering the level of GAPDH mRNA

constant. All calculations of HCV RNA are expressed as fold difference over a specific control.

Antibodies and Immunological Techniques

5 Mouse monoclonal antibody (anti-NS3 mab10E5/24) were produced by standard techniques. (Galfré and Milstein, 1981. *Methods in Enzymology* 73, 1-46.) Purified recombinant protein was used as an immunogen. (Gallinari, *et al.*, 1999. *Biochemistry* 38, 5620-5632.)

 For Cell-ELISA analysis, transfected cells were monitored for
10 expression of the NS3 protein by ELISA with the anti-NS3 mab 10E5/24. Cells were seeded into 96 well plates at densities of 40,000, 30,000, 15,000 and 10,000 cells per well and fixed with ice-cold isopropanol at 1, 2, 3 and 4 days post-transfection, respectively. The cells were washed twice with PBS, blocked with 5% non-fat dry milk in PBS + 0.1% Triton X100 + 0.02% SDS (PBSTS) and then incubated
15 overnight at 4°C with 10E5/24 mab diluted 1:2000 in Milk/PBSTS. After washing 5 times with PBSTS, the cells were incubated for 3 hours at room temperature with anti-mouse IgG Fc specific alkaline phosphatase conjugated secondary antibody (Sigma A-7434), diluted 1:2000 in Milk/PBSTS. After washing again as above, the reaction was developed with *p*-nitrophenyl phosphate disodium substrate (Sigma 104-
20 105) and the absorbance at 405 nm read at intervals.

 The results were normalized by staining with sulforhodamine B (SRB Sigma S 1402) to determine cell numbers. The alkaline phosphatase substrate was removed from the wells and the cells washed with PBS. The plates were then incubated with 0.4% SRB in 1% acetic acid for 30 minutes (200 µl/well), rinsed 4
25 times in 1% acetic acid, blotted dry and then 200 µl/well of 10mM Tris pH 10.5 added. After mixing, the absorbance at 570 nm was read.

Neutral Red/ Crystal Violet Staining of Foci

 The survival of transfected cells in the absence or presence of G418
30 was monitored by staining of foci/clones with neutral red *in vivo* with subsequent crystal violet staining. The medium was removed from the cells and replaced with fresh medium containing 0.0025% neutral red (Sigma N2889) and the cells incubated for 3 hours at 37°C. Cells were washed twice with PBS, fixed in 3.5% formaldehyde for 15 minutes, washed twice again in PBS and then with distilled water and the
35 number of (live) foci counted. The cells could then be re-stained with crystal violet

by incubating with an 0.1% crystal violet (Sigma C0775) solution in 20% methanol for 20 minutes at room temperature, followed by 3 washes in 20% methanol and a wash with distilled water.

5 *Preparation Of Cells Cured Of Endogenous Replicon*

Replicon enhanced cells designated 10IFN and Cl.60/cu were produced using different HCV inhibitory agents. Based on the techniques described herein additional replicon enhanced clones can readily be obtained.

10IFN was obtained by curing a Huh-7 cell of a replicon using human
10 IFN- α 2b. Huh-7 cells containing HCV replicons (designated HBI10, HBIII4, HBIII27 and HBIII18) were cultured for 11 days in the presence of 100 U/ml recombinant human IFN- α 2b (Intron-A, Schering-Plough), and subsequently for 4 days in the absence of IFN- α 2b. At several time points during this period, the clones were analyzed for the presence of HCV proteins and RNA by Western and Northern
15 blotting. After 7 days of incubation with IFN- α 2b, HCV proteins could no longer be detected in any of these clones by Western blotting and similar effects were seen with RNA signals in Northern blots. IFN- α 2b treated cells were stored in liquid nitrogen until used for transfection experiments.

Cl.60/cu was obtained by curing a Huh-7 cell of a replicon using an
20 HCV inhibitory compound. The presence of HCV RNA was determined using PCR (TaqMan) at 4, 9, 12 and 15 days. From day 9 the amount of HCV RNA was below the limit of detection. To further test the disappearance of the replicon, 4 million cells of cured Clone 60 cells (after the 15 days of treatment) were plated in the presence of 1 mg/ml G-418. No viable cells were observed, confirming that absence of HCV
25 replicons able to confer G-418 resistance.

Example 2: Selection and Characterization of Cell Clones Containing Functional HCV Replicons

Huh-7 cells ($2-8 \times 10^6$) were transfected by electroporation with *in vitro*
30 transcribed replicon RNAs (10–20 μ g), plated at a density ranging from 2.5×10^3 to $10 \times 10^3/\text{cm}^2$, and cultured in the presence of 0.8–1 mg/ml G418. The majority of replicon transfected cells became transiently resistant to G418 and duplicated normally for 7 to 12 days in the presence of the drug, while cells transfected with irrelevant RNAs and mock transfected cells did not survive more than 7 days (data not
35 shown). Transient resistance to G418 was likely due to persistence of the Neo protein

expressed from the transfected RNA, since it was observed also with mutated replicons unable to replicate. Approximately 2 weeks after transfection, transient resistance declined, most cells died and small colonies of cells permanently resistant to the antibiotic became visible in samples transfected with HCVNeo.17 RNA, but
5 not in cells transfected with other replicon RNAs.

In several experiments, the frequency of G418 resistant clones ranged between 10 and 100 clones per 10^6 transfected cells. About 20 G418 resistant colonies were isolated, expanded and molecularly characterized. PCR and RT-PCR analysis of nucleic acids indicated that all clones contained HCV RNA but not HCV
10 DNA, demonstrating that G418 resistance was due to the presence of functional replicons (data not shown). This result was confirmed by Northern blot analysis and metabolic labeling with ^3H -uridine, which revealed the presence of both genomic and antigenomic HCV RNAs of the expected size (data not shown). Lastly, western blot, immunoprecipitation and immunofluorescence experiments showed that these clones
15 expressed all HCV non-structural proteins as well as Neo protein (data not shown).

Clones differed in terms of cell morphology and growth rate. Replicon RNA copy number (500-10000 molecules/cell) and viral protein expression also varied between different clones (data not shown). However, the amount of replicon RNA and proteins also varied with passages and with culture conditions and was
20 higher when cells were not allowed to reach confluency, suggesting that replicons replicated more efficiently in dividing cells than in resting cells. Processing of the viral polyprotein occurred with kinetics similar to those observed in transfected cells.

Interestingly, in all tested clones HCV replication was efficiently inhibited by treating the cells with IFN- $\alpha 2\text{b}$. The EC_{50} was between 1 and 10 U/ml,
25 depending on the clone.

Example 3: Identification of Adaptive Mutations

The low number of G418 resistant clones derived from HCVNeo.17 RNA transfection suggested that replication could require mutation(s) capable of
30 adapting the replicon to the host cell (adaptive mutations) and/or that only a small percentage of Huh-7 cells were competent for HCV replication. To verify the first hypothesis, mutations in replicons RNAs derived from selected cell clones were identified.

RNA sequences for different replicons were determined using standard techniques. Such techniques involved isolating RNA from several independent clones, reverse transcription to produce cDNA, amplifying cDNAs by PCR and cloning into an appropriate vector. The cDNA spanning almost the entire HCV NS region (126 bp at the 3' end of the EMCV IRES and 5650 bp of the HCV NS region (*i.e.*, the entire NS ORF and 298 nucleotides at the 3' end) from 5 clones (HBI10, HBIII12, HBIII18, HBIII27, HBIV1) were recloned and sequenced. In addition, the NS5A coding region (nt. 4784-6162) from 3 additional clones (HB 77, HB 68 and HB 60) were recloned and sequenced.

To discriminate mutations present in the replicon RNA from those derived from the cloning procedure, at least 2 isolates derived from independent RT-PCR experiments were sequenced for each cell clone. Comparison of the nucleotide sequences with the parental sequence indicated that each isolate contained several mutations (Tables 4A and 4B).

TABLE 4A

Cell clone	HBIII 12		HBIII 18		HBI 10		HBIII 27	
isolate	4	29	28	61	12	43	13	72
	1674-7460	1674-7460	1674-7460	1674-7460	1674-7460	1674-7460	1674-7460	1674-7460
EMCV IRES 126 bp	A @ 1736	A @ 1736		C 1752 T				T 1678 C
NS3 1895 bp	G 2009 C A 2698 G G 2764 A A 3256 G T 3273 C	A 2330 G C 2505 T G 2764 A T 3085 C	T 2150 C C 2196 A T 3023 A T 3134 C C 3267 T	T 2015 C A 2338 G C 2616 T A 2664 G A 3148 G T 3286 C C 3615 T C 3657 T	T 1811 A A 2330 G T 2666 C T 3395 C	A 2330 G A 2882 G T 3673 C	G 2009 C T 2015 C C 2336 G A 3130 T A 3401 G A 3518 C	G 2009 C C 2052 A G 2644 A C 2803 A T 2823 A T 3692 C
NS4A 161 bp	T 3790 C		A 3847 G	T 3827 A	T 3742 C		A 3743 G	A 3797 G
NS4B 782 bp	T 3869 C A 4107 G T 4185 C A 4428 G	C 4283 T C 4429 T	G 4300 A	A 4136 G A 4261 G G 4309 A A 4449 G	T 4290 C	A 4053 G A 2496 C T 4316 G	G 3880 A T 4200 C A 4366 G	C 4547 T

TABLE 4A

Cell clone	HBIII 12		HBIII 18		HBI 10		HBIII 27	
isolate	4	29	28	61	12	43	13	72
	1674-7460	1674-7460	1674-7460	1674-7460	1674-7460	1674-7460	1674-7460	1674-7460
NS5A 1340 bp	A 4847 C G 5158 A G 5175 C C 5243 T C 5390 T A 5719 G	G 4728 A A 4845 G C 5243 T G 5512 T A 5521 G A 5600 G A 5740 C	C 5243 T A 5486 G C 5596 T G 5823 A	C 4729 A T 4993 C G 5095 A T 5334 C A 5374 T T 5379 A T 5480 C A 5513 G T 5977 C	A 4694 T AAA @ 4842 T 5237 C	A 4675 G A 4761 G AAA @ 4842 T 5368 C	A 4855 G C 5006 T T 5318 C A 5574 G G 5866 A	A 4888 G C 4985 T T 5030 A T 5090 A T 5318 C A 5328 G A 5399 G A 5574 G
NS5B 1477 bp	T 6316 C T 6589 C T 7370 C	A 6406 G G 6756 A G 6963 T	T 6074 C A 6541 G A 6732 G A 7350 T A 7359 G	A 6150 G A 6218 G T 7352 A	A 6911 G	A 5986 G T 6099 C C 6141 T G 6463 A C 6849 T T 6865 C	G 6479 C C 6870 T A 7213 G T 7448 C	G 6156 A G 7434 A T 7444 C

Clone name and isolate number are indicated in the first and second row, respectively.

The first and the last nucleotide of the region that was recloned and sequenced are indicated in the third row.

5

Nucleotide (IUB code) substitutions are indicated with the original nucleotide, its position and mutated nucleotide.

Nucleotide(s) insertions are indicated with the nucleotide(s), the symbol @ and the position of the nucleotide preceding insertion.

10

Numbering refers to the first nucleotide of the replicon sequence (EMBL-genbank No. AJ242652).

The region in which mutations are located and the nucleotide length of each region are indicated in the left most column.

Silent mutations are in *italic*.

Non sense mutations are underlined.

15

Consensus mutations are **bold**.

TABLE 4B

Cell clone	HBIV1		HB 77		HB 68		HB 60	
isolate	85	93	10	14	42	1	13	7
	1674-7460	1674-7460	4784-6162	4465-6162	4784-6162	4465-6162	4784-6162	4784-6162
EMCV IRES 126 bp		A @ 1736						
NS3 1895 bp	A 3403 G	A 2572 G A 3454 G						

TABLE 4B

Cell clone	HBIV1		HB 77		HB 68		HB 60	
isolate	85	93	10	14	42	1	13	7
	1674-7460	1674-7460	4784-6162	4465-6162	4784-6162	4465-6162	4784-6162	4784-6162
NS4A 161 bp								
NS4B 782 bp	A 4084 G	C 3892 T						
NS5A 1340 bp	T 4742 C C 5315 T G 5431 T T 5751 C T 5797 C	A 4847 C A 5225 G C 5315 T G 5320 A T 5356 A G 5523 A T 5888 A	C 4813 T G 5060 C C 5337 A	A 4699 C A 5161 G C 5337 A A 5459 G T 5977 C	T 5171 G C 5298 T C 5337 A A 5639 G A 5969 G	T 4587 C T 4972 C A 5094 G A 5278 G G 5320 A C 5532 T	A 4821 G G 5320 A A 5414 G T 5601 G C 5808 T	C 5337 G C 5551 T G 5806 A
NS5B 1477 bp	T 6144 A A 6365 G A 6656 G A 6677 G T 6855 C T 6947 A T 6997 C G 7041 T A 7187 C	T 6855 C A 7135 G T 7171 C						

See Table 4A legend.

- 5 The frequency of mutations ranged between 1.7×10^{-3} and 4.5×10^{-3} (average 3×10^{-3}). The majority of mutations were nucleotide substitutions, although insertions of 1 or more nucleotides were also observed (Tables 4A and 4B).

- 10 Approximately 85% of the mutations found only in 1 isolate (non-consensus) were randomly distributed in the recloned fragment, and possibly include mis-incorporation during the PCR amplifications. Conversely, the remaining 15% of the mutations were common to 2 or more isolates derived from independent RT-PCR experiments (consensus mutations), and presumably reflected mutations present in the template RNA.

- 15 Consensus mutations were found in all isolates and were either common to isolates derived from the same clone (consensus A), or to isolates derived from different clones (consensus B). Analysis of additional isolates derived from the same cell clones indicated that consensus A mutations were not always present in all isolates derived from one clone (data not shown). This observation, together with the

presence of consensus B mutations, suggests that, even within a single cell clone, replicons exist as quasi-species of molecules with different sequences.

At variance with non-consensus mutations, consensus mutations were not randomly distributed but were clustered in the regions coding for the NS5A protein (frequency 1×10^{-3}) and for the NS3 protein (frequency 0.5×10^{-3}). Only one consensus mutation was found in the region coding for the NS5B protein (frequency 0.1×10^{-3} nucleotides) and none in the regions coding for NS4A and NS4B. Interestingly, 1 consensus mutation was observed also in the EMCV IRES.

With the exception of 2 silent mutations found in NS5A and NS5B, consensus mutations occurring in the NS region resulted in changes in the deduced amino acid sequence (Tables 5A and 5B). Noticeably, these amino acid changes occurred in residues that are conserved in all or most natural HCV isolates. Interestingly, clones HB 77 and HB 60 displayed different nucleotide substitutions (C5337A and C5337G, respectively) resulting in the same amino acidic mutation (S 2204 R).

TABLE 5A

Cell clone	HBIII 12		HBIII 18		HBI 10		HBIII 27	
isolate	4	29	28	61	12	43	13	72
NS3	G 1095 A A 1347 T	E 1202 G A 1347 T			E 1202 G	E 1202 G	G 1095 A	G 1095 A
NS4A								
NS4B								
NS5A	N 2041 T S 2173 F	S 2173 F	S 2173 F	E 2263	K @ 2039	K @ 2039	L 2198 S R 2283 R	L 2198 S R 2283 R
NS5B								

See Table 4A legend.

TABLE 5B

Cell clone	HBIV1		HB 77		HB 68		HB 60	
isolate	85	93	10	14	42	1	13	7
NS3								
NS4A								
NS4B								
NS5A	S 2197 F	N 2041 T S 2197 F A 2199 T	S 2204 R	S 2204 R	S 2204 R	A 2199 T	A 2199 T	S 2204 R
NS5B	N 2710 N	N 2710 N						

See Table 4A legend.

5 Example 4: Functional Characterization of Consensus Mutations

The identification of consensus mutations in recloned replicons indicated that replication proficiency of replicon RNAs contained in selected cell clones depended from the presence of such mutations. To substantiate this hypothesis, the effect of several consensus mutations on replication were analyzed.

- 10 Consensus mutations found in the NS5A region were more closely analyzed. Consensus mutations were segregated from the non-consensus ones, and pHCVNeo.17 derivatives containing single or multiple consensus mutations were constructed (Table 6).

TABLE 6

Construct	Consensus mutations			G418 cfu/10 ³ transfected cells
	NS3	NS5A	EMCV IRES	
pHCVNeo17.wt				0-3
pHCVNeo17.GAA				0
pHCVNeo17.m0		S2204R		30-130
pHCVNeo17.m1		N2041T		0-3
pHCVNeo17.m2		S2173F		15-60
pHCVNeo17.m3		S2197F		160-500
pHCVNeo17.m4		L2198S		30-50

TABLE 6

Construct	Consensus mutations			G418 cfu/10 ⁵ transfected cells
	NS3	NS5A	EMCV IRES	
pHCVNeo17.m5		<u>K@2039</u>		25-55
pHCVNeo17.m6	E1202G; A1347T	S2173F	Extra A	13-100
pHCVNeo17.m7		N2041T; S2173F		0-1
pHCVNeo17.m8		N2041T; S2197F		360-500
pHCVNeo17.m9		N2041T; L2198S		140-170
pHCVNeo17.m10	E1202G	<u>K@2039</u>		1060
pHCVNeo17.m11		S2197F; A2199T		900
pHCVNeo17.m12		N2041T; S2197F; A2199T		>1000
pHCVNeo17.m13		N2041T; S2197F	Extra A	100
pHCVNeo17.m14		S2197F; A2199T	Extra A	>500
pHCVNeo17.m15		A2199T		300-600

Huh-7 cells (2×10^6) were transfected with 10 μ g of RNA transcribed from the indicated constructs. Approximately 2×10^5 cells were plated in a 10 cm tissue culture dish and cultured with 1 mg/ml G418 for 20 days.

Colonies surviving selection were stained with crystal violet and counted.

5

RNAs transcribed *in vitro* from these constructs were transfected in Huh-7 cells and the affect on replication was estimated by counting neomycin resistant colonies (G418 cfu). As shown in Table 6, all but 1 construct containing single consensus mutations showed a significant increase on G418 cfu efficiency, thus indicating that the corresponding mutations improved replication. Noticeably, 2 mutants containing single mutations in NS5A (m3 and m15) were clearly more effective than all other single mutants. Results of mutants containing 2 or more mutations, indicated the presence of a synergistic effect in some combinations (m8, m9, m11 and possibly m10), but also a slightly antagonistic effect in 1 mutant (m7).

15

Example 5: Replicon Replication in the Absence of Selection

Replication of HCV replicons in the absence of a G418 selection was detected using quantitative PCR (TaqMan). At 24 hours post-transfection a large amount of replicon RNA was detected in cells transfected with all replicons, including the GAA control replicon containing mutations in the catalytic GDD motif of the NS5B polymerase. This result suggested that analysis at very early time points (up to 48 hour post-transfection) essentially measured the input RNA. Northern blot analysis also indicated that after 24 hours the majority of the transfected RNA was degraded intracellularly (data not shown).

20

Analysis at later time points showed that the amount of replicon RNA was considerably reduced at 4 days and eventually became undetectable (6/8 days) in cells transfected with replicon HCVNeo17.wt, but was still high in cells transfected with replicons m0, m3 and m15 (Table 7). At day six, that the amount of replicon RNA became undetectable in cells transfected with replicon HCVNeo17.wt, m0, and m2, but was detectable in cells transfected with replicon m3 and m15 (Table 7).

TABLE 7

Name	Hu H7	
	RNA equ.	RNA equ.
	day 4	day 6
Wt	1 x	1 x
hcvneo17.m0	3 x	1 x
hcvneo17.m2	1 x	1 x
hcvneo17.m3	5 x	3 x
hcvneo17.m15	6 x	5 x

10

Persistence of m0, m3 and m15 replicons RNA was abolished by treatment with interferon- α or with an HCV inhibitory compound (data not shown). Moreover, RNA persistence was not observed with mutated replicons carrying the NS5B GAA mutation besides adaptive mutations (data not shown). Taken together, these results demonstrated that quantitative PCR could be used to monitor replication at early times post-transfection, and can be used to evaluate the replication proficiency of replicon RNAs containing mutations.

Comparison of the results shown in Tables 6 and 7, indicated that there was a good correlation between the amount of replicon RNA detected by TaqMan and the G418 cfu efficiency. Nonetheless, some mutants (m2, m3) showed a pronounced effect on G418 cfu efficiency, and little if any effect on early replication as measured by TaqMan PCR, while other mutants (m0) showed the reverse behavior.

20

Example 6: HCV Replicon Enhanced Cells

HCV replicon enhanced cells were produced by introducing an HCV replicon into a host, then curing the host of the replicon. Adaptive mutations (or combinations of them) by themselves increased up to 2 orders of magnitude the G418 cfu efficiency and enhanced early replication comparably. Nonetheless, even with the most effective mutants, only a small percentage of transfected cells (<5 %, data not shown) gave rise to G418 resistant clones containing functional replicons. This observation was attributed, at least in part to a low cloning efficiency of Huh-7 cells (data not shown), and only a fraction of Huh-7 cells being competent for replication.

Several clones were cured of endogenous replicons by treating them for about 2 weeks with IFN- α or with a HCV inhibitory compound. Analysis at the end of the treatment showed that neither viral proteins nor replicon RNA could be detected.

Cured cells (10IFN and Cl.60/cu) were transfected with mutated replicons and replication efficiency was determined by counting neomycin resistant clones (10IFN) or by TaqMan (10IFN and Cl.60/cu). As shown in Table 8, for all tested replicons the G418 cfu efficiency in 10IFN cells was at least 5 fold higher than in parental Huh-7 cells. This increase in G418 cfu efficiency was particularly relevant for a subset of mutants (m3, m5, m8, m9, m15).

TABLE 8

Construct	Consensus mutations			G418 cfu/10 ⁵ transfected cells
	NS3	NS5A	EMCV IRES	
pHCVNeo17.wt				12 - 56
pHCVNeo17.GAA				0
pHCVNeo17.m0		S2204R		180 - 1000
pHCVNeo17.m1		N2041T		8 - 13
pHCVNeo17.m2		S2173F		2000
pHCVNeo17.m3		S2197F		1600 - 3000
pHCVNeo17.m4		L2198S		190 - 650
pHCVNeo17.m5		K@2039		1600 - 3000
pHCVNeo17.m6	E1202G; A1347T	S2173F	extra A	600 - 2000
pHCVNeo17.m7		N2041T; S2173F		170 - 800
pHCVNeo17.m8		N2041T; S2197F		> 4000
pHCVNeo17.m9		N2041T; L2198S		1400 - 3000
pHCVNeo17.m10	E1202G	K@2039		>4000
pHCVNeo17.m11		S2197F; A2199T		>4000

TABLE 8

Construct	Consensus mutations			G418 cfu/10 ⁵ transfected cells
	NS3	NS5A	EMCV IRES	
pHCVNeo17.m12	N2041T; S2197F; A2199T			>4000
pHCVNeo17.m13	N2041T; S2197F extra A			>4000
pHCVNeo17.m14	S2197F; A2199T extra A			>4000
pHCVNeo17.m15	A2199T			> 4000

10IFN cells (2×10^6) were transfected with 10 μ g of RNA transcribed from the indicated constructs. Approximately 2×10^5 cells were plated in a 10 cm tissue culture dish and cultured with 1 mg/ml G418 for 20 days.

Colonies surviving selection were stained with crystal violet and counted.

Strikingly, the best mutants yielded a number of G418 resistant clones ranging between 20 and 80% of the cell clones which grew in the absence of G418 (data not shown), thus indicating that the majority of 10IFN cells were competent for replication. This result was confirmed by TaqMan analysis (Table 9), in which the fold increase versus the parental Huh-7 cells was very high. The data indicates that replicons carrying adaptive mutations replicate vigorously in replicon enhanced cells such as 10IFN and Cl.60/cu.

TABLE 9

Name	10IFN		Cl.60/cu.	
	RNA equ.	RNA equ.	RNA equ.	RNA equ.
	Day 4	day 6	day 4	Day 6
Wt	1 x	1 x	1 x	1 x
hcvneo17.m0	46 x	12 x	78 x	512 x
hcvneo17.m2	2 x	2 x	1 x	2 x
hcvneo17.m3	68 x	49 x	19 x	392 x
hcvneo17.m15	247 x	80 x	268 x	5518 x

Expression of viral proteins was determined in replicon enhanced cells using an ELISA assay designed to detect the NS3 protein in transfected cells plated in 96 wells microtiter plates (Cell-ELISA). As shown in Table 10, 24 hours post-transfection cells transfected with all tested replicons expressed low but detectable levels of the NS3 protein.

TABLE 10

Name	NS3 arbitrary units			
	24 h p.t.		96 h p.t.	
	-	+ IFN	-	+IFN
Construct				
Mock	1	1	1	1
pHCVNeo17.wt	3.7	4.2	1.2	1.3
pHCVNeo17.GAA	3.1	3.2	1.1	1
pHCVNeo17.m0	3.4	3.2	9.9	0.8
pHCVNeo17.m3	5.7	4.6	4.7	1.5
pHCVNeo17.m8	6.6	5.1	15.1	1.4
pHCVNeo17.m10	8	5.6	9.2	1.8
pHCVNeo17.m11	8.4	6.2	13.6	1.8

10IFN cells (2×10^6) were transfected with 10 μ g of RNA transcribed from the indicated constructs. Cells were plated in 96 wells microtiter plates as indicated in Example 1.

- 5 Where indicated (+IFN), IFN- α (100 U/ml) was added to the culture medium 4 hours post-transfection. At the indicated times post-transfection, cells were fixed and analyzed by Cell-ELISA.

The early expression shown in Table 10 is likely due to translation of transfected RNA, since it was comparable in all replicons (including that carrying the GAA mutation) and was not affected by IFN- α . At 4 days post-transfection, NS3
 10 expression persisted or increased in cells transfected with replicons carrying consensus mutations, but could not be detected anymore in cells transfected with wt and GAA replicons. In addition, NS3 expression was almost completely abolished when cells were cultured in the presence of IFN- α .

Taken together, these results indicated that the level of NS3 expression
 15 reflected the replication rate. Indeed, NS3 expression level (Table 10) paralleled the RNA level measured by TaqMan (Table 9). The high replication proficiency of 10IFN cells was further confirmed by immunofluorescence experiments which showed that more than 50% of cells transfected with replicons m8 and m11 expressed high level of viral proteins, and that expression was almost completely abolished by
 20 IFN- α .

Example 7: Replication of Full Length Constructs

This example illustrates the ability of a full length HCV genome containing adaptive mutations described herein to replicate in a replicon enhanced
 25 host cell. The full length sequence of the HCV isolate Con-1 (EMBL-Genbank No. AJ238799) (plasmid pHCVRBFL.wt) and 2 derivatives containing either the N2041T

and S2173 F mutations (plasmid pHCVRBFL.m8) or the S2197F and A2199T mutations (plasmid pHCVRBFL.m11) were used as starting constructs.

- 5 RNAs transcribed from the starting constructs were transfected in 10IFN cells and their replication proficiency was assessed by Cell-ELISA, immunofluorescence and TaqMan. Both constructs containing consensus mutations (pHCVRBFL.m8 and pHCVRBFL.m11) replicated, while no sign of replication was observed with the wt. construct (data not shown).

Example 8: Replicons with Reporter Gene

- 10 This example illustrates an HCV replicon containing adaptive mutations and a reporter gene. A pHCVNeo17.wt derivative where the Neo coding region was substituted with that coding for human placental secretory alkaline phosphatase (pRBSEAP5.wt) and a derivative also containing the N2041T and S2173F mutations (plasmid pRBSEAP5.m8) were constructed. RNAs transcribed
15 from these plasmids were transfected in 10IFN cells and their replication proficiency was assessed by measuring secretion of alkaline phosphatase. Analysis of the kinetics of secretion suggested that only plasmid pRBSEAP5.m8 was competent for replication (data not shown).

20 Example 9: SEQ. ID. Nos. 1 and 2

SEQ. ID. NOs. 1 and 2 are provided as follows:

SEQ. ID. NO. 1

- 25 MSTNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLGVRATRKT
SERSQPRGRRQPIPKARQPEGRAWAQP GYPWPLYGNEGLGWAGWLLSPRGS
RPSWGPTDPRRRSRNLGKVIDTLTCGFADLMGYIPLVGAPLGGAARALAHGV
RVLEDGVNYATGNLPGCSFSIFLLALLSCLTIPASAYEVRNVSGVYHVTNDCS
NASIVYEAADMIMHTPGCVPCVRENNSSRCWVALTPTLAARNASVPTTTIRR
HVDLLVGAAALCSAMYVGDLCGSVFLVAQLFTFSPRRHETVQDCNCSIYPGH
30 VTGHRMAWDMMMNWSPTAALVVSQLLRIPQAVVDMVAGAHWGVLAGLA
YYSMVGNWAKVLIVMLLFAGVDGGTYVTGGTMAKNTLGITSLFSPGSSQKIQ
LVNTNGSWHINRTALNCNDSLNTGFLAALFYVHKFNSSGCPERMASCSPIDAF
AQGWGPITYNESHSSDQRPYCWHYAPRPGIVPAAQVCGPVYCFTSPVVG
TTDRFGVPTYSWGENETDVLLLNNTRPPQGNWFGCTWMNSTGFTKTCGGPP

CNIGGIGNKTLTCPTDCFRKHPEATYTKCGSGPWLTTPRCLVHYPYRLWHYPC
TVNFTIFKVRMYVGGVEHRLEAACNWTRGERCNLEDRDRSELSPLLLSTTEW
QVLPCSFTTLPALSTGLIHLHQNVDVQYLYGIGSAVVSFAIKWEYVLLLFLLL
ADARVCACLWMMLLIAQAEAALENLVVLNAASVAGAHGILSFLVFFCAAWY
5 IKGRLVPGAAYALYGVWPLLLLLLALPPRAYAMDREMAASCGGAVFVGLILL
TLSPHYKLFLARLIWWLQYFITRAEAHLQVWIPPLNVRGGRDAVILLTCAIHPE
LIFTITKILLAILGPLMVLQAGITKVPYFVRAHGLIRACMLVRKVAGGHYVQM
ALMKLAALTGTYYVDHLTPLRDWAHAGLRDLAVAVEPVVFSDMETKVITW
GADTAACGDILGLPVSARRGREIHLGPADSLEGQGWRLAPITAYSQQTRGL
10 LGCIITSLTGRDRNQVEGEVQVSTATQSFLATCVNGVCWTVYHGAGSKTLA
GPKGPIQMYTNVDQDLVGWQAPPGARSLTPCTCGSSDLYLVTRHADVIPVR
RRGDSRGSLLSPRPVSYLKGSSGGPLLCPSGHAVGIFRAAVCTRGVAKAVDFV
PVESMETTMRSVFTDNSSPPAVPQTFQVAHLHAPTGSGKSTKVPAAAYAAQG
YKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGAPITYSTYKGFLA
15 DGGCSGGAYDIICDECHSTDSTTILGIGTVLDQAETAGARLVVLATATPPGSV
TVPHPNIEEVALSSTGEIPFYGKAIPETIKGGRHLIFCHSKKKCDELAACKLSGLG
LNAVAYYRGLDVSVIPTSGDVIVVATDALMTGFTGDFDSVIDCNTCVTQTVD
FSLDPTFTIETTTVPQDAVSRSQRRGRTGRGRMGIYRFVTPGERPSGMFDSVL
CECYDAGCAWYELTPAETSVRLRAYLNTPLPVCQDHLFEWESVFTGLTHID
20 AHFLSQTKQAGDNFPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHG
PTPLLYRLGAVQNEVTTHPITKYIMACMSADLEVVTSTWVLVGGVLAALAA
YCLTTGSVVIVGRILSGKPAIPDREVLYREFDEMEECASHLPYIEQGMQLAEQ
FKQKAIGLLQTATKQAEAAAPVESKWRTEAFWAKHMWNFISGIQYLAGLS
TLPGNPAIASLMAFTASITSPLTTQHTLLFNILGGWVAAQLAPPSAASAFVGAG
25 IAGAAVGSIGLGKVLVDILAGYGAGVAGALVAFKVMMSGEMPSTEDLVNLLPA
ILSPGALVVGVCAILRRHVGPGEVAVQWMNRLIAFASRGNHVSPTHYVPE
SDAAARVTQILSSLTITQLLKRLHQWINEDCSTPCSGSWLRDVWDWICTVLTD
FKTWLQSKLLPRLPGVPPFSCQRGYKGVWRGDGIMQTTCPGAQITGHVKNQ
SMRIVGPRTCSNTWHGTFPINAYTTGPCTPSPAPNYSRALWRVAAEEYVEVT
30 RVGDFHYVTGMTTDNVKCPQVPAPEFFTEVDGVRLHRYAPACKPLLREEV
TFLVGLNQYLVGSQLPCEPEPDVAVLTSMLTDPSHITAETAKRRLARGSPPSL
ASSASQLSAPSLKATCTTRHDSPDADLIEANLLWRQEMGGNITRVESENKVV
ILDSFEPLQAEEDEREVSVP AEILRRSRKFPRAMPIWARPDYNPPLLESWKDPD
YVPPVVHGCPLPPAKAPPIPPRRKRTVVLESTVSSALAEATKTFGSSSEA
35 VDSGTATASPDQPSDDGDAGSDVESYSSMPPLEGEPDPLSDGSWSTVSEE

ASDEVVCCSMSYTWGTALITPCAAEETKLPINALSNSLLRHHNLVYATTSRSA
 SLRQKKVTFDRLQVLDDHYRDVLKEMKAKASTVKAKLLSVEEACKLTPPHS
 ARSKFGYGAKDVRNLSSKAVNHRSVWVDLLEDTETPIDTTIMAKNEVFCVQ
 PEKGGRRKPARLIVFIDLGVVRVCEKMALYDVVSTLPQAVMGSSYGFQYSPGQR
 5 VEFLVNAWKAKKCPMGFA YDTRCFDSTVTENDIRVEESIYQCCDLAPEARQA
 IRSALTERLYIGGPLTNSKGQNCGYRRCRASGVLTTS CGNTLTCYLKAAAACRA
 AKLQDCTMLVCGDDL V VICESAGTQEDEASLRAFTEAMTRY SAPPDPPKPE
 YDLELITSCSSNVSV AHDASGKR VYYLTRDPTT PLARAAWETARHTPVNSWL
 GNIIMYAPTLWARMILMTHFFSILLAQE QLEKALDCQIYGACYSIEPLDLPQIIQ
 10 RLHGLSAFSLHSYSPGEINR VASCLRKLGVPLRVWRHRARSVRARLLSQQGR
 AATCGKYLFNWAVRTKLKLTPIPAASQLDLSSWFVAGYSGGDIYHSLSRARP
 RWFMWCLLLLSVGVGIYLLPNR

SEQ. ID. NO. 2:

15 gccagcccccgaattggggcgacactccaccatagatcactccccgtgaggaactactgtcttcacgcagaaagcgtcta
 gccatggcgtaglatgagtgctgcagcctccaggacccccctccgggagagccatagtggtctgcggaaccgggtg
 agtacaccggaattgccaggacgaccgggtccttcttgatcaaccgctcaatgcctggagatttgggcgtgccccgcg
 agactgctagccgagtagtggtgggtcgcaaggccttggtactgcctgatagggtgcttgcgagtgccccgggaggt
 ctctagaccgtgcaccatgagcacgaatcctaaacctcaagaaaaacaaacgtaacaccaaccgcccccacagga
 20 cgtcaagttccccggcggtggtcagatcgtcgttgagttacctgttgcgcgcaggggccccaggttgggtgctgcgcg
 gactaggaagacttccgagcgtgcgaacctcgtggaaggcgacaacctatccccaggctcgcagcccagggttagg
 gcctgggctcagccgggtacccttgccccctctatggcaatgagggttgggggggaggtggtcctgtcacccctg
 ggctctggcctagtggggccccacggacccccggcgtaggctgcgcgaatttgggtaaggctacgataccctcacgtgc
 ggcttcgccgatctcatggggtacattccgctcgtcggcggccccctaggggggcgtgccaggggcctggcgcatggcgt
 25 ccgggttctggaggacggcgtgaactatgcaacagggaatctgccgggtgctcctttctatcttcttttggcttgcgtcct
 gtttgaccatcccagcttccgcttatgaagtgcgcaacgtatccggagtgtaccatgtcacgaacgactgtccaacgcaag
 cattgtgatgaggcagcggacatgatcatgcatccccgggtgcgtgccctgcgttcgggagaacaacctctcccgtgc
 tgggtagcgtcactcccacgctcgcggccaggaaacgtagcgtcccccactacgacgatacagcgcctatgcgatttgc
 gttggggcggtgctctctgctccgtatgtacgtgggagatctctgcggatctgttctcctcgtcggcagctgttcacctctc
 30 gcctcgcgggcacgagacagtlacaggactgcaattgctcaatatatcccgccacgtgacaggtcacctgatggcttggga
 tatgatgatgaactggcacctacagcagccctagtggatcgagttactccggatcccaagctgtcgtggataggtgg
 cggggggccattggggagtcctagcgggccttgctactattccatgggtgggaactgggctaagggttctgattgtgatgcta
 ctcttggccgggtgacgggggaacctatgtgacaggggggacgatggccaaaaacacctcgggattacgtccctcttt
 caccgggtcatccagaaaatccagcttgaacaccaacggcagctggcacatcaacaggactgccctgaactgcaat
 35 gactccctcaacactgggttccctgctgcgtgttctacgtgcacaagttcaactcatctggatcccagagcgcgatggccag

ctgcagcccatcgacgcgttcgctcaggggtgggggcccacacttacaatgagtcacacagctcggaccagaggcctta
 ttgttgccactacgcaccccgccgtgcggtaicgtaccccgggcgaggtgtgtggccagtgtactgcttccccaaagc
 cctgtcgtgggggacgaccgaccgggtcggcgctccctacgtacagtgggggggagaatgagacggacgtgctgcttctt
 aacaacacggggccgccaaggcaactgggttggtgtacatggatgaatagcactgggttcaccaagacgtgccccggg
 5 cccccgtgaacatcggggggatcggcaataaaccttgacctgccccacggactgcttccggaagcaccggaggcca
 ctacaccaagtgtgttcggggccttgggtgacaccagatgcttgggtccactaccatacaggcttggcactaccctgc
 actgtcaactttaccatcttcaaggtaggatgtacgtggggggagtgaggcacaggctcgaagccgatgcaattggactc
 gaggagagcgttgaactggaggacaggacagatcagagcttagcccgctgctgtgtclacaacggagtggcaggta
 ttgccctgttcttaccacccctaccggctctgtccactgggttgatccatctccatcagaacgtcgtggacgtacaatctgt
 10 acggtatagggtcggcggtgtctccttgcaatcaaatgggagtatgtcctgttcttcttcttctggcggacgcgcgct
 ctgtgcctgcttggatgatgtgctgatagctcaagctgaggccgccctagagaacctgggtgtcctaacgcggcatcc
 gtggccggggcgcatggcattctcttcttctgtgttcttctgtgctgcttggatcatcaagggcaggctggctcctggggc
 ggcatatgccctctacggcgtatggccgctactcctgtcctgctggcggttaccaccacgagcatacgccatggaccggga
 gatggcagcatcgtgcggaggcgcggtttctgtaggtctgatactcttgacctgtcaccgactataagctgttctcgtag
 15 gctcatatgggtgttacaatatltatcaccaggggccgaggcacacttgcaagtgtggatccccccctcaacgttcgggggg
 gccgcatggcgcatcctcctacgtgcgcgalccaccagagctaactttaccatcaccaaaatcttctcgcatactc
 ggtccactcatggtgtccaggctgtataaccaagtccgctactcgtgcgcgcacacgggtcattcgtgcatgcatgct
 ggtgcggaagggtgtgggggtcattatgtccaaatggctctcatgaagtggccgcactgacaggtagtacgtttatgacc
 atctcaccctactgcgggactggggccacgcgggctacgagaccttgcgggtggcagttgagcccgtcgttctctgatat
 20 ggagaccaagggttatcactggggggcagacaccgcggcggtgtggggacatcatcttgggcctgcccgtlccgcccgca
 gggggaggagatacatctgggaccggcagacagcctgaagggcaggggtggcgactcctcgcgcctattacggccta
 ctcccaacagacgcgaggcctacttgggtgcatcatcactagcctcacaggccgggacagggaaccaggctcggggggag
 gtccaagtgtgtccaccgcaacacaatcttcttggcgacctgcgtcaatggcgtgtgttggactgtctatcatggtgccgg
 ctcaaagaccttgcggggccaaaggggccaaacacccaaatgtacaccaatgtggaccaggacctcgtcggttggaag
 25 cggccccggggcggttcttgacaccatgcacctgcggcagctcggaccttacttgggtcacgaggcatgccgatgcat
 tccggtgcgcggcgggggcgacagcagggggagcctactctccccaggccgtctcctacttgaagggtcttctgggc
 ggtccactgctctgcccctcggggcacgctgtgggcatcttctgggctgccgtgtgcaccgagggggtgcgaaggcgggtg
 gacttltgaccgtcaggtctatggaaccactatcggttccccgggttctcacggacaactcgtcccctccggccgtaccgc
 agacattccagggtggcccatctacagcccctactgglagcggcaagagcactaagggtccggctgcgtatgcagcccaa
 30 ggggtataagggtgttctgaacccgtccgtcggccaccctaggtttcggggcgatatgtctaaggcacatggtatcga
 ccctaacatcagaaccggggtaggaccatcaccacgggtgccccatcacgtactccacctatggcaagtttcttggcgac
 ggtgtgtgcttggggggcgcctatgacatcataatatgtgatagtgccactcaactgactcgaacctatcctgggcatcgg
 cacagtctggaccaagcggagacggctggagcgcgactcgtcgtcgtcgcaccgctacgctccgggaltcgggtacc
 gtgccacatccaaacatcgaggagggtggctctgtccagcactggagaaatcccccttltatggcaaagccatccccatcgaga
 35 ccatcaagggggggaggcacctcatcttctgccattccaagaagaaatgtgatgagctcggcggaagctgtccggcctcg

gactcaatgctgtagcatattaccggggccttgatgtatccgtcataccaactagcggagacgtcattgtcgtagcaacggac
 gctctaatacggggccttaccggcgatttcgactcagtgatcgactgcaatacatgtgtcaccagacagtcgacttcagcct
 ggacccgaccttcacattgagacgacgaccgtgccacaagacgggtgtcacgctcgcagcggcgaggcaggactggg
 aggggcaggatgggcaattacaggtttgtgactccaggagaacggccctcgggcatgttcgattcctcggttctgtcgagt
 5 gctatgacgcgggctgtgcttggtacgagctcacgcccgcgagacctcagttagggttcggggcttacctaaacacaccag
 gggtgcccgtctgccaggaccatctggagttctgggagagcgtctttacaggcctcaccacatagacgcccatttctgtcc
 cagactaagcaggcaggagacaactccccctacctggtagcataccaggctacgggtgtgccaggggctcaggctccacc
 tccatcgtgggaccaaatgtggaagtgtctcatcaggctaaagcctacgctgcacgggccaacgcccctgctgtataggctg
 ggagccgttcaaacgaggttactaccacacccccataaccaatacatcatggcatgcatgtcggctgacctggaggctc
 10 gtcacgagcacctgggtgctggtaggcggagtcctagcagctctggccgcgtattgcctgacaacaggcagcgtggtcatt
 gtgggcaggatcatcttctccggaaagccggccatcattcccagagggaagtcctttaccgggagttcgtatgagatggaa
 gagtgcgcctcacacctcccttaccatcgaacagggaatgcagctcgcgaacaattcaaacagaaggcaatcgggttgctg
 caaacagccaccaagcaagcgggaggtgctgctcccgtggtggaatccaagtggcggaccctcgaagccttctgggcga
 agcatatgtggaatttcacagcgggatacaataatttagcaggctgtccactctgcctggcaaccccgcgatagcatcactga
 15 tggcattcacagcctctatcaccagcccgtcaccaccaacataccctcctgtttaacatcctggggggatgggtggccgc
 ccaacttgctcctcccagcgtgcttctgcttctgtaggcgccggcatcgctggagcggctgttggcagcataggccttggg
 aagggtgcttggatattttggcaggltatggagcaggggtggcaggcgcgctcgtggcctttaagggtcatgagcggcgag
 atgcccctccaccgaggacctgggttaacctactccctgctatcctcctcccctggcgccctagtcgtcggggctcgtgtgcgcagc
 gatactgcgtcggcacgtggggccaggggagggggctgtgcagtggtgaaccggctgalagcgttgcgttcgggggta
 20 accacgtctccccacgcactatgtccctgagagcgacgctgcagcacgtgtcactcagatcctctctagtcttaccatcact
 cagctgctgaagaggcttcaccagtggaacagaggactgctccacgccatgctccggctcgtggctaagagatgttgg
 gattggatagcagcgtgttgactgattcaagacctggctccagtcgaagctcctgccgcgaltgccgggagtccttcttct
 tcatgtcaacgtgggtacaaggagctgtggcggggcgacggcatcatgcaaacacctgcccatgtggagcacagatcac
 cggacatgtgaaaaacgggttccatgaggatcgtggggcctaggacctgtagtaaacagtggtcatggaacatccccattaac
 25 gcgtacaccacggggccctgcacgcccctcccgccgcaaatattctaggcgctgtggcgggtggctgctgaggagta
 cgtggaggttacgcgggtgggggatttccactacgtgacgggcatgaccactgacaacgtaaagtccccgtgcaggttcc
 ggccccgaattcttcacagaagtggatggggtgcgggtgcacagggtacgctccagcgtgcaaacccctcctacgggagg
 aggtcacattcctggtcgggtcaatcaatacctgggtgggtcacagctccatgcgagcccgaaccggacgtagcagtgct
 cacttccatgctcaccgacctcccacattacggcgagacgggctaagcgtaggctggccaggggatctccccctcctt
 30 ggccagctcatcagctagccagctgtctgcgcttccctgaaggcaacatgcactacccgtcatgactccccggagcgtgac
 ctcatcgaggccaacctcctgtggcgagcaggatggcggggaacatcaccgcgtggagtcagaaaataaggtagtaatt
 ttggactcttctgagccgctccaagcggaggaggatgagagggaaglatccgttccggcgagatcctgcggagggtcca
 ggaaattccctcgagcgatgcccatatgggcacgcccggaltacaacctccactgttagagtcctggaaaggacccggact
 acgtccctccagtggtacacgggtgtccattgccgctgccaaggccccctccgataccacctccacggaggaagaggacg
 35 gttgtcctgtcagaatctaccgtgtcttctgccttggcgagctcgccacaagaccttcggcagctccgaatcgtcggccgt

cgacagcggcacggcaacggcctctcctgaccagccctccgacgacggcgacgcgggacgccgattgagtcgtactcc
tccatgcccccccttgaggggggagccgggggatcccgatctcagcgacgggtcttggtctaccgtaagcgaggaggctag
tgaggacgtcgtctgctcgtatgtcctacacatggacaggcgccctgatcacgccatcgctcgggaggaaccaagct
gcccataatgcaactgagcaactcttctgctccgtcaccacaacttggctctatgtacaacatctcgacgcgaagcctgcggc
5 agaagaagggtcacctttgacagactgcaggtcctggacgaccactaccgggacgtgctcaaggagatgaaggcgaaggc
gtccacagttaaggctaaacttctatccgtggaggaagcctgtaagctgacgccccacattcgccagatctaaatttggct
atggggcaaaggacgtccggaacctatccagaaggccgttaaccacatccgctccgtgtggaaggacttgcgtgaagac
actgagacaccaattgacaccaccatcatggcaaaaaatgaggttttctcgctcaaccagagaagggggggccgaagcc
agctcgccttatcgtattcccagatttgggggttcgtgtgtcgagaaaatggccctttacgatgtggtctccaccctccctcag
10 gccgtgatgggctcttcatacggattccaatactctcctggacagcgggtcgagttcctggatgcctggaaagcgaaga
aatgccctatgggcttcgcatatgacaccgcgttttgaactcaacggctactgagaatgacatccgtgttgaggagtcaatct
accaatgttgtacttggccccgaagccagacaggccataaggctcgtcacagagcggctttacatcgggggccccctga
ctaattctaagggcagaactgcgggtatcgccgggtgccgcgcgagcgggtgactgacgaccagctgcggtaataacctca
catgttacttgaaggccgctgcggcctgtcgagctgcgaagctccaggactgcacgatgctcgtatgcggagacaccttgt
15 cgttatctgtgaaagcgcggggacccaagaggacgaggcgagcctacgggccttcacggaggctatgactagatactctg
ccccccctggggaccgcccaaacagaatacgaacttggagttgataacatcatgctcctccaatgtgtcagtcgcgcacg
atgcatctggcaaaagggtgtactatctcaccgtgacccaccaccccccttgcgcgggctgcgtgggagacagctagac
aactccagtcaattcctggctaggaacatcatcatgtatgcgccaccttggggcaaggatgatcctgatgactcatttct
ctccatccttctagctcaggaacaacttgaaaaagccctagattgcagatctacggggcctgttactccattgagccacttga
20 cctacctcagatcattcaacgactccatggccttagcgcattttactccatagttactctccaggtagatcaatagggtggct
tcatgcctcaggaaacttgggtaccgcccttgcgagctgtggagacatcggggcagaagtgtccgcgctaggctactgtcc
caggggggggagggtgccacttgtggcaagtacctcttaactgggcagtaaggaccaagctcaaaactactccaatcccg
gctcgcgtcccagttggattatccagctggttcgttgcgtggttacagcgggggagacatatcagacgcctgtctcgtgccga
ccccgctggttcatgtgtgctactcctactttctgtaggggtaggcatctatctactcccaaccgatgaacggggagctaa
25 aactccaggccaataggccatcctgtttttccctt
ttcctttttttccttttgggtggctccatcttagccctagtcacgggtagctgtgaaaggctccgtgagccgcttgaactgcagagagt
gctgatactggcctctctgcagatcaagt

Other embodiments are within the following claims. While several
30 embodiments have been shown and described, various modifications may be made
without departing from the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. A nucleic acid molecule comprising a region selected from the group consisting of:
 - 5 a) an altered HCV NS3 encoding region coding for one or more NS3 mutations, wherein at least one of said NS3 mutations, identified by reference to the amino acid sequence numbering of SEQ. ID. NO. 1, is selected from the group consisting of:
 - amino acid 1095 being Ala,
 - 10 amino acid 1202 being Gly, and
 - amino acid 1347 being Thr;
 - b) an altered HCV NS5A encoding region coding for one or more NS5A mutations, wherein at least one of said NS5A mutations, identified by reference to the amino acid sequence numbering of SEQ. ID. NO. 1, is selected from the group
15 consisting of:
 - amino acid 2041 being Thr,
 - a Lys insertion between residue 2039 and 2040.
 - amino acid 2173 being Phe,
 - amino acid 2197 being Phe,
 - 20 amino acid 2198 being Ser,
 - amino acid 2199 being Thr, and
 - amino acid 2204 being Arg; and
 - c) an altered encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) region containing one or more EMCV IRES mutations,
25 wherein at least one of said EMCV IRES mutations, identified by reference to the nucleotide number of SEQ. ID. NO. 3, is an insertion at nucleotide 1736 of adenine.
2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises said NS5A encoding region.
30
3. The nucleic acid molecule of claim 2, wherein at least two of said NS5A adaptive mutations are present.

4. The nucleic acid molecule of claim 2, further comprising a region encoding for a HCV NS3 region, wherein said NS3 region may be the same or different than said altered NS3 region.
5. The nucleic acid molecule of claim 4, wherein said nucleic acid molecule is an HCV replicon comprising a HCV 5' UTR-PC region, said NS3 encoding region, an HCV NS4A encoding region, an HCV NS4B encoding region, said NS5A encoding region, an HCV NS5B encoding region, and a HCV 3' UTR.
6. The nucleic acid molecule of claim 5, wherein said HCV replicon further comprises a sequence encoding for a reporter protein.
7. The nucleic acid molecule of claim 5, wherein said HCV replicon further comprises a sequence encoding for a selection protein.
8. The nucleic acid molecule of claim 5, wherein said HCV replicon further comprises a HCV core encoding region, a HCV E1 encoding region, a HCV E2 encoding region, a HCV p7 encoding region, and a HCV NS2 encoding region.
9. A nucleic acid molecule comprising a region selected from the group consisting of:
- a) an altered HCV NS3 encoding region containing one or more NS3 mutations, wherein at least one of said NS3 mutations, identified by reference to the nucleotide numbering of SEQ. ID. NO. 2, is selected from the group consisting of: nucleotide 3625 being cytosine, nucleotide 3946 being guanine, nucleotide 4380 being adenine,
 - b) an altered HCV NS5A encoding region containing one or more NS5A mutations, wherein at least one of said NS5A mutations, identified by reference to the nucleotide numbering of SEQ. ID. NO. 2, is selected from the group consisting of: an insertion of 3 adenine residues between nucleotide 6458 and 6459, nucleotide 6463 being cytosine, nucleotide 6859 being thymine or uracil,

nucleotide 6931 being thymine or uracil,
nucleotide 6934 being cytosine,
nucleotide 6936 being adenine, and
nucleotide 6953 being adenine or guanine; and

- 5 c) an altered encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) region containing one or more EMCV IRES mutations, wherein at least one of said EMCV IRES mutations, identified by reference to the nucleotide number of SEQ. ID. NO. 3, is an insertion at nucleotide 1736 of adenine.

- 10 10. The nucleic acid molecule of claim 9, wherein said molecule comprises said altered NS5A encoding region, and the nucleotide sequence of said altered NS5A region is provided for by bases 6258-7598 of SEQ. ID. NO. 2, or the RNA version thereof, modified with one or more of said NS5A modifications selected from the group consisting of:

- 15 an insertion of 3 adenine residues between nucleotide 6458 and 6459,
nucleotide 6463 being cytosine,
nucleotide 6859 being thymine or uracil,
nucleotide 6931 being thymine or uracil,
nucleotide 6934 being cytosine,
20 nucleotide 6936 being adenine, and
nucleotide 6953 being adenine or guanine.

11. The nucleic acid molecule of claim 10, wherein said molecule is an HCV replicon comprising a HCV 5' UTR-PC region, a modified HCV NS3-
25 NS5B region, and a HCV 3' UTR, wherein said modified NS3-NS5B region comprises said altered NS5A region.

12. The nucleic acid molecule of claim 11, wherein said 5' UTR-PC region is the RNA version of bases 1-377 of SEQ. ID. NO. 2 and said 3' UTR is
30 the RNA version of bases 9374-9605 of SEQ. ID. NO. 2.

13. The nucleic acid molecule of claim 10, wherein said molecule is an HCV replicon comprising a HCV 5' UTR-PC region, a modified HCV NS3-NS5B region, and a HCV 3' UTR, wherein
35 said 5' UTR-PC region is the RNA version of bases 1-377 of SEQ. ID. NO. 2;

said 3' UTR is the RNA version of bases 9374-9605 of SEQ. ID. NO. 2; and
 said modified NS3-NS5B region consists of the RNA version of bases 3420-9371 of
 SEQ. ID. NO. 2 modified with one or more modifications selected from the group
 consisting of:

- 5 nucleotide 4380 being adenine,
 nucleotide 3625 being cytosine,
 nucleotide 3946 being guanine,
 an insertion of 3 adenine residues between nucleotide 6458 and nucleotide 6459,
 nucleotide 6463 being cytosine,
- 10 nucleotide 6859 being uracil,
 nucleotide 6931 being uracil,
 nucleotide 6934 being cytosine,
 nucleotide 6936 being adenine, and
 nucleotide 6953 being adenine or guanine.

15

14. The nucleic acid molecule of claim 13, wherein said replicon is
 a genomic replicon that further comprises the RNA version of nucleotides 378-3419
 of SEQ. ID. NO. 2.

20

15. A nucleic acid molecule comprising the nucleic acid base
 sequence of bases 1-7989 of SEQ. ID. NO. 3, or the RNA version thereof, consisting
 of one or more different modifications selected from the group consisting of:

- a) nucleotides 5335-5337 modified to code for arginine;
- b) nucleotides 5242-5244 modified to code for phenylalanine;
- 25 c) nucleotides 5314-5316 modified to code for phenylalanine;
- d) nucleotides 5317-5319 modified to code for serine;
- e) nucleotides coding for lysine inserted after nucleotide 4843;
- f) nucleotides 2329-2331 modified to code for glycine, nucleotides 2764-2766
 modified to code for threonine, nucleotides 5242-5244 modified to code for
- 30 phenylalanine, and an extra adenosine inserted after nucleotide 1736;
- g) nucleotides 4846-4848 modified to code for threonine, and nucleotides 5242-5244
 modified to modified to code for phenylalanine;
- h) nucleotides 4846-4848 modified to code for threonine, and nucleotides 5314-5316
 modified to code for phenylalanine;

- i) nucleotides 4846-4848 modified to code for threonine, and nucleotides 5317-5319 modified to code for serine;
- j) nucleotides 2329-2331 modified to code for glycine, and nucleotides coding for lysine inserted after nucleotides 4843;
- 5 k) nucleotides 5314-5316 modified to code for phenylalanine and nucleotides 5320-5322 modified to code for threonine;
- l) nucleotides 4846-4848 modified to code for threonine, nucleotides 5314-5316 modified to code for phenylalanine, and nucleotides 5320-5322 modified to code for threonine;
- 10 m) nucleotides 4846-4848 modified to code for threonine, nucleotides 5314-5316 modified to code for phenylalanine, and an extra adenosine inserted after nucleotide 1736; and
- n) nucleotides 5314-5316 modified to code for phenylalanine, nucleotides 5320-5322 modified to code for threonine, and an extra adenosine inserted after nucleotide 1736;
- 15 and
- o) nucleotides 5320-5322 modified to code for threonine.

16. The nucleic acid of claim 15, wherein said one or more different modifications is selected from the group consisting of:

- 20 a) C5337A;
- b) C5243T or U;
- c) C5315T or U;
- d) T or U5318C;
- e) AAA inserted after 4843;
- 25 f) A2330G, G2764A, C5243T or U, and adenosine inserted 1736;
- g) A4847C and C5243T or U;
- h) A4847C and C5315T or U;
- i) A4847C and T or U5318C;
- j) A2330G and AAA inserted after 4843;
- 30 k) C5315T or U and G5320A;
- l) A4847C, C5315T or U, and G5320A;
- m) A4847C, C5315T or U, and adenosine inserted 1736;
- n) C5315T or U, G5320A and adenosine inserted 1736; and
- o) G5320A.

17. The nucleic acid of claim 16, wherein said nucleic acid is RNA and comprises said nucleic acid base sequence.

5 18. The nucleic acid of claim 17, wherein said nucleic acid is RNA and consists of said nucleic acid base sequence.

19. An expression vector comprising a nucleotide sequence coding for the nucleic acid molecule of any one of claims 1-18, wherein said nucleotide
10 sequence is transcriptionally coupled to an exogenous promoter.

20. A recombinant cell human hepatoma cell, wherein said cell comprises the nucleic acid of any one of claims 5-8 and 11-18.

15 21. The recombinant cell of claim 20, wherein said hepatoma cell is an Huh-7 cell.

22. The recombinant cell of claim 20, wherein said cell is derived from a Huh-7 cell.

20

23. A recombinant cell made by a process comprising the step of introducing into a human hepatoma cell the nucleic acid of any one of claims 5-8 and 11-18.

25 24. A method of making an HCV replicon enhanced cell comprising the steps of:
a) introducing and maintaining a HCV replicon in a cell; and
b) curing said cell of said HCV replicon to produce said replicon enhanced cell.

30

25. The method of claim 24, wherein said cell is a human hepatoma cell.

26. The method of claim 24, wherein said cell is a Huh-7 cell or is
35 derived from a Huh-7 cell.

27. The method of claim 26, further comprising the step of confirming the ability of said replicon enhanced cell to maintain an HCV replicon.

5 28 A method of making an HCV replicon enhanced cell containing a functional HCV replicon comprising the steps of:

- a) introducing and maintaining a first HCV replicon in a cell;
- b) curing said cell of said first replicon to produce a cured cell;

and

10 c) introducing and maintaining a second HCV replicon into said cured cell, wherein said second HCV replicon may be the same or different than said first HCV replicon.

15 29 The method of claim 28, wherein said cell is a human hepatoma cell.

30. The method of claim 29, wherein said human hepatoma cell is a Huh-7 cell.

20 31. The method of claim 30, wherein said human hepatoma cell is derived from a Huh-7 cell.

25 32. An HCV replicon enhanced cell made by the method of any one of claims 24-27.

33. An HCV replicon enhanced cell containing a HCV replicon made by the method of any one of claims 28-31.

30 34. A method of measuring the ability of a compound to affect HCV activity comprising the steps of:

- a) providing said compound to the HCV replicon enhanced cell of claim 33; and
- b) measuring the ability of said compound to effect one or more replicon activities as a measure of the effect on HCV activity.

35

35. The method of claim 34, wherein said compound is a ribozyme.
36. The method of claim 34, wherein said compound is an
antisense nucleic acid.
- 5 37. The method of claim 34, wherein compound is an organic
compound.
- 10 38. The method of claim 34, wherein said step (b) measures HCV
protein production.
39. The method of claim 33, wherein said step (b) measures
production of RNA transcripts.

1 GCCAGCCCC GATTGGGGG GACACTCCAC CATAGATCAC TCCCCTGTGA
51 GGAACTACTG TCTTCACGCA GAAAGCGTCT AGCCATGGCG TTAGTATGAG
101 TGTCTGTCAG CCTCCAGGAC CCCCCCTCCC GGGAGAGCCA TAGTGGTCTG
151 CGGAACCGGT GAGTACACCG GAATTGCCAG GACGACCGGG TCCTTTCTTG
201 GATCAACCCG CTCAATGCCT GGAGATTTGG GCGTGCCCC GCGAGACTGC
251 TAGCCGAGTA GTGTGGGGT GCGAAAGGCC TTGTGGTACT GCCTGATAGG
301 GTGCTTGCGA GTGCCCCGGG AGGTCTCGTA GACCGTGCAC CATGAGCAGG
351 AATCCTAAAC CTCAAAGAAA AACCAAAGGG CGCGCCATGA TTGAACAAGA
401 TGGATTGCAC GCAGGTTCTC CGGCCGCTTG GGTGGAGAGG CTATTCGGCT
451 ATGACTGGGC ACAACAGACA ATCGGCTGCT CTGATGCCGC CGTGTTCGGG
501 CTGTACAGCG AGGGGCGCCC GGTCTTTTT GTCAAGACCG ACCTGTCCGG
551 TGCCCTGAAT GAACTGCAGG ACGAGGCAGC GCGGCTATCG TGGCTGGCCA
601 CGACGGGCGT TCCTTGCGCA GCTGTGCTCG ACGTTGTCAC TGAAGCGGCA
651 AGGGACTGGC TGCTATTGGG CGAAGTGCCG GGCAGGATC TCCTGTCATC
701 TCACCTTGCT CCTGCCGAGA AAGTATCCAT CATGGCTGAT GCAATGCGGC
751 GGCTGCATAC GCTTGATCCG GCTACCTGCC CATTCGACCA CCAAGCGAAA
801 CATCGCATCG AGCGAGCAG TACTCGGATG GAAGCCGGTC TTGTCGATCA
851 GGATGATCTG GACGAAGAGC ATCAGGGGCT CGCGCCAGCC GAACTGTTCTG
901 CCAGGCTCAA GCGCGCATG CCCGACGGCG AGGATCTCGT CGTGACCCAT
951 GGCGATGCCT GCTTGCCGAA TATCATGGTG GAAAATGGCC GCTTTCTTGG
1001 ATTCATCGAC TGTGGCCGGC TGGGTGTGGC GGACCGCTAT CAGGACATAG
1051 CGTTGGCTAC CCGTGATATT GCTGAAGAGC TTGGCGGCGA ATGGGCTGAC
1101 CGCTTCCTCG TGCTTTACGG TATCGCCGCT CCCGATTCTG AGCGCATCGC
1151 CTTCTATCGC CTTCTTGACG AGTTCTTCTG AGTTTAAACA GACCACAACG
1201 GTTCCCTCT AGCGGGATCA ATTCCGCCCC TCTCCCTCCC CCCCCCTAA
1251 CGTTACTGGC CGAAGCCGCT TGAATAAGG CCGGTGTGCG TTTGTCTATA
1301 TGTTATTTTC CACCATATTG CCGTCTTTTG GCAATGTGAG GGCCCGAAA
1351 CCTGGCCCTG TCTTCTTGAC GAGCATTCCT AGGGGTCTTT CCCCTCTCGC
1401 CAAAGGAATG CAAGGTCTGT TGAATGTCGT GAAGGAAGCA GTTCCTCTGG
1451 AAGCTTCTTG AAGACAAACA ACGTCTGTAG CGACCCTTTG CAGGCAGCGG
1501 AACCCCCAC CTGGCGACAG GTGCCTCTGC GGCCAAAAGC CACGTGTATA

FIG. 1A

1551 AGATACACCT GCAAAGGCGG CACAACCCCA GTGCCACGTT GTGAGTTGGA
1601 TAGTTGTGGA AAGAGTCAAA TGGCTCTCCT CAAGCGTATT CAACAAGGGG
1651 CTGAAGGATG CCCAGAAGGT ACCCCATTGT ATGGGATCTG ATCTGGGGCC
1701 TCGGTGCACA TGCTTTACAT GTGTTTAGTC GAGGTTAAAA AACGTCTAGG
1751 CCCCCGAAC CACGGGGACG TGGTTTTCCT TTGAAAAACA CGATAATACC
1801 ATGGCGCCTA TTACGGCCTA CTCCAACAG ACGCGAGGCC TACTTGGCTG
1851 CATCATCACT AGCCTCACAG GCCGGGACAG GAACCAGGTC GAGGGGGAGG
1901 TCCAAGTGGT CTCCACCGCA ACACAATCTT TCCTGGCGAC CTGCGTCAAT
1951 GGCGTGTGTT GGA CTGTCTA TCATGGTGCC GGCTCAAAGA CCCTTGCCGG
2001 CCCAAAGGGC CCAATCACCC AAATGTACAC CAATGTGGAC CAGGACCTCG
2051 TCGGCTGGCA AGCGCCCCC GGGGCGCGTT CCTTGACACC ATGCACCTGC
2101 GGCAGCTCGG ACCTTTACTT GGTCACGAGG CATGCCGATG TCATTCCGGT
2151 GCGCCGGCGG GCGACAGCA GGGGAGCCT ACTCTCCCC AGGCCCGTCT
2201 CCTACTTGAA GGGCTCTTCG GCGGTCCAC TGCTCTGCCC CTCGGGGCAC
2251 GCTGTGGGCA TCTTTCGGG TGCCGTGTGC ACCCGAGGGG TTGCGAAGGC
2301 GGTGGACTTT GTACCCGTCG AGTCTATGGA AACCACATG CGGTCCCCGG
2351 TCTTCACGGA CAACTCGTCC CCTCCGGCCG TACCGCAGAC ATTCCAGGTG
2401 GCCCATCTAC ACGCCCCTAC TGGTAGCGGC AAGAGCACTA AGGTGCCGGC
2451 TGCGTATGCA GCCCAAGGGT ATAAGGTGCT TGTCTGAAC CCGTCCGTCG
2501 CCGCCACCCT AGGTTTCGGG GCGTATATGT CTAAGGCACA TGGTATCGAC
2551 CCTAACATCA GAACCGGGGT AAGGACCATC ACCACGGGTG CCCCCATCAC
2601 GTACTCCACC TATGGCAAGT TTCTTGCCGA CGGTGGTTGC TCTGGGGGCG
2651 CCTATGACAT CATAATATGT GATGAGTGCC ACTCAACTGA CTCGACCACT
2701 ATCCTGGGCA TCGGCACAGT CCTGGACCAA GCGGAGACGG CTGGAGCGCG
2751 ACTCGTCGTG CTCGCCACCG CTACGCCCTCC GGGATCGGTC ACCGTGCCAC
2801 ATCCAAACAT CGAGGAGGTG GCTCTGTCCA GCACTGGAGA AATCCCCTTT
2851 TATGGCAAAG CCATCCCCAT CGAGACCATC AAGGGGGGGA GGCACCTCAT
2901 TTTCTGCCAT TCCAAGAAGA AATGTGATGA GCTCGCCGCG AAGCTGTCCG
2951 GCCTCGGACT CAATGCTGTA GCATATTACC GGGGCCTTGA TGTATCCGTC
3001 ATACCAACTA GCGGAGACGT CATTGTCGTA GCAACGGACG CTCTAATGAC
3051 GGGCTTTACC GCGATTTCG ACTCAGTGAT CGACTGCAAT ACATGTGTCA

FIG. 1B

3101 CCCAGACAGT CGACTTCAGC CTGGACCCGA CCTTCACCAT TGAGACGACG
3151 ACCGTGCCAC AAGACGCGGT GTCACGCTCG CAGCGGCGAG GCAGGACTGG
3201 TAGGGGCAGG ATGGGCATTT ACAGGTTTGT GACTCCAGGA GAACGGCCCT
3251 CGGGCATGTT CGATTCTCTG GTTCTGTGCG AGTGCTATGA CGCGGGCTGT
3301 GCTTGGTACG AGCTCACGCC CGCCGAGACC TCAGTTAGGT TGCGGGCTTA
3351 CCTAAACACA CCAGGGTTGC CCGTCTGCCA GGACCATCTG GAGTTCCTGG
3401 AGAGCGTCTT TACAGGCCTC ACCCACATAG ACGCCCATTT CTTGTCCCAG
3451 ACTAAGCAGG CAGGAGACAA CTTCCCCTAC CTGGTAGCAT ACCAGGCTAC
3501 GGTGTGCGCC AGGGCTCAGG CTCCACCTCC ATCGTGGGAC CAAATGTGGA
3551 AGTGTCTCAT ACGGCTAAAG CCTACGCTGC ACGGGCCAAC GCCCCTGCTG
3601 TATAGGCTGG GAGCCGTTCA AAACGAGGTT ACTACCACAC ACCCCATAAC
3651 CAAATACATC ATGGCATGCA TGTCGGCTGA CCTGGAGGTC GTCACGAGCA
3701 CCTGGGTGCT GGTAGGCGGA GTCCTAGCAG CTCTGGCCGC GTATTGCCTG
3751 ACAACAGGCA GCGTGGTCAT TGTGGGCAGG ATCATCTTGT CCGGAAAGCC
3801 GGCCATCATT CCCGACAGGG AAGTCCTTTA CCGGGAGTTC GATGAGATGG
3851 AAGAGTGCGC CTCACACCTC CCTTACATCG AACAGGGAAT GCAGCTCGCC
3901 GAACAATTCA AACAGAAGGC AATCGGGTTG CTGCAAACAG CCACCAAGCA
3951 AGCGGAGGCT GCTGCTCCCG TGGTGGAATC CAAGTGGCGG ACCCTCGAAG
4001 CCTTCTGGGC GAAGCATATG TGGAATTTCA TCAGCGGGAT ACAATATTTA
4051 GCAGGCTTGT CCACTCTGCC TGGCAACCCC GCGATAGCAT CACTGATGGC
4101 ATTCACAGCC TCTATACCA GCCCGCTCAC CACCCAACAT ACCCTCCTGT
4151 TTAACATCCT GGGGGGATGG GTGGCCGCCC AACTTGCTCC TCCCAGCGCT
4201 GCTTCTGCTT TCGTAGGCGC CGGCATCGCT GGAGCGGCTG TTGGCAGCAT
4251 AGGCCTTGGG AAGGTGCTTG TGGATATTTT GGCAGGTTAT GGAGCAGGGG
4301 TGGCAGGCGC GCTCGTGGCC TTAAAGGTCA TGAGCGGCGA GATGCCCTCC
4351 ACCGAGGACC TGGTTAACCT ACTCCCTGCT ATCCTCTCCC CTGGCGCCCT
4401 AGTCGTCGGG GTCGTGTGCG CAGCGATACT GCGTCGGCAC GTGGGCCAG
4451 GGGAGGGGGC TGTGCA GTG ATGAACCGC TGATAGCGTT CGCTTCGCGG
4501 GGTAACCACG TCTCCCCAC GCACTATGTG CCTGAGAGCG ACGCTGCAGC
4551 ACGTGCTACT CAGATCCTCT CTAGTCTTAC CATCACTCAG CTGCTGAAGA
4601 GGCTTCACCA GTGGATCAAC GAGGACTGCT CCACGCCATG CTCCGGCTCG

FIG. 1C

4651 TGGCTAAGAG ATGTTTGGGA TTGGATATGC ACGGTGTTGA CTGATTTCAA
4701 GACCTGGCTC CAGTCCAAGC TCCTGCCGCG ATTGCCGGA GTCCCCTTCT
4751 TCTCATGTCA ACGTGGGTAC AAGGGAGTCT GGCGGGGCGA CGGCATCATG
4801 CAAACCACCT GCCCATGTGG AGCACAGATC ACCGGACATG TGAAAAACGG
4851 TTCCATGAGG ATCGTGGGGC CTAGGACCTG TAGTAACACG TGGCATGGAA
4901 CATTCCTCAT TAACGCGTAC ACCACGGGCC CCTGCACGCC CTCCCCGGCG
4951 CCAAATTATT CTAGGGCGCT GTGGCGGGTG GCTGCTGAGG AGTACGTGGA
5001 GGTTACGCGG GTGGGGGATT TCCACTACGT GACGGGCATG ACCACTGACA
5051 ACGTAAAGTG CCCGTGTCAG GTTCCGGCCC CCGAATTCTT CACAGAAGTG
5101 GATGGGGTGC GGTGTCACAG GTACGCTCCA GCGTGCAAAC CCCTCCTACG
5151 GGAGGAGGTC ACATTCTTGG TCGGGCTCAA TCAATACCTG GTTGGGTAC
5201 AGCTCCCATG CGAGCCCGAA CCGGACGTAG CAGTGCTCAC TTCCATGCTC
5251 ACCGACCCCT CACACATTAC GGCGGAGACG GCTAAGCGTA GGCTGGCCAG
5301 GGGATCTCCC CCCTCCTTGG CCAGCTCATC AGCTAGCCAG CTGTCTGCGC
5351 CTTCTTTGAA GGCAACATGC ACTACCGTC ATGACTCCCC GGACGCTGAC
5401 CTCATCGAGG CCAACCTCCT GTGGCGGCAG GAGATGGGCG GGAACATCAC
5451 CCGCGTGGAG TCAGAAAATA AGGTAGTAAT TTTGGACTCT TTCGAGCCGC
5501 TCCAAGCGGA GGAGGATGAG AGGGAAGTAT CCGTTCCGGC GGAGATCCTG
5551 CGGAGGTCCA GGAAATTCCC TCGAGCGATG CCCATATGGG CACGCCCCGA
5601 TTACAACCCT CCACTGTTAG AGTCCTGGAA GGACCCGGAC TACGTCCCTC
5651 CAGTGGTACA CGGGTGTCCA TTGCCGCCTG CCAAGGCCCC TCCGATACCA
5701 CCTCCACGGA GGAAGAGGAC GGTGTCTCTG TCAGAATCTA CCGTGTCTTC
5751 TGCCTTGGCG GAGCTCGCCA CAAAGACCTT CGGCAGCTCC GAATCGTCGG
5801 CCGTCGACAG CGGCACGGCA ACGGCCCTCTC CTGACCAGCC CTCCGACGAC
5851 GGCGACGCGG GATCCGACGT TGAGTCGTAC TCCTCCATGC CCCCCCTTGA
5901 GGGGAGCCG GGGGATCCCG ATCTCAGCGA CGGGTCTTGG TCTACGTAA
5951 GCGAGGAGGC TAGTGAGGAC GTCGTCTGCT GCTCGATGTC CTACACATGG
6001 ACAGGCGCCC TGATCACGCC ATGCGCTGCG GAGGAAACCA AGCTGCCCAT
6051 CAATGCACTG AGCAACTCTT TGCTCCGTCA CCACAACCTG GTCTATGCTA
6101 CAACATCTCG CAGCGCAAGC CTGCGGCAGA AGAAGGTCAC CTTTGACAGA
6151 CTGCAGGTCC TGGACGACCA CTACCGGGAC GTGCTCAAGG AGATGAAGGC

FIG. 1D

6201 GAAGGCGTCC ACAGTTAAGG CTAAACTTCT ATCCGTGGAG GAAGCCTGTA
6251 AGCTGACGCC CCCACATTCG GCCAGATCTA AATTTGGCTA TGGGGCAAAG
6301 GACGTCCGGA ACCTATCCAG CAAGGCCGTT AACCACATCC GCTCCGTGTG
6351 GAAGGACTTG CTGGAAGACA CTGAGACACC AATTGACACC ACCATCATGG
6401 CAAAAAATGA GGTTTTCTGC GTCCAACCAG AGAAGGGGGG CCGCAAGCCA
6451 GCTCGCCTTA TCGTATTCCC AGATTTGGGG GTTCGTGTGT GCGAGAAAAT
6501 GGCCCTTTAC GATGTGGTCT CCACCCTCCC TCAGGCCGTG ATGGGCTCTT
6551 CATA CGGATT CCAATACTCT CCTGGACAGC GGGTCGAGTT CCTGGTGAAT
6601 GCCTGGAAAG CGAAGAAATG CCCTATGGGC TTCGCATATG ACACCCGCTG
6651 TTTTGACTCA ACGGTCAC TG AGAATGACAT CCGTGTTGAG GAGTCAATCT
6701 ACCAATGTTG TGA CTGGCC CCCGAAGCCA GACAGGCCAT AAGGTCGCTC
6751 ACAGAGCGGC TTTACATCGG GGGCCCCCTG ACTAATTCTA AAGGGCAGAA
6801 CTGCGGCTAT CGCCGGTGCC GCGCGAGCGG TGTACTGACG ACCAGCTGCG
6851 GTAATACCCT CACATGTTAC TTGAAGGCCG CTGCGGCCCTG TCGAGCTGCG
6901 AAGCTCCAGG ACTGCACGAT GCTCGTATGC GGAGACGACC TTGTCGTTAT
6951 CTGTGAAAGC GCGGGGACCC AAGAGGACGA GGCGAGCCTA CGGGCCTTCA
7001 CGGAGGCTAT GACTAGATAC TCTGCCCCC CTGGGGACCC GCCCAAACCA
7051 GAATACGACT TGGAGTTGAT AACATCATGC TCCTCCAATG TGTAGTCGCG
7101 GCACGATGCA TCTGGCAAAA GGGTGTA CTA TCTCACCCTG GACCCACCA
7151 CCCCCCTTGC GCGGGCTGCG TGGGAGACAG CTAGACACAC TCCAGTCAAT
7201 TCCTGGCTAG GCAACATCAT CATGTATGCG CCCACCTTGT GGGCAAGGAT
7251 GATCCTGATG ACTCATTTCT TCTCCATCCT TCTAGCTCAG GAACAACTTG
7301 AAAAAGCCCT AGATTGTCAG ATCTACGGGG CCTGTTACTC CATTGAGCCA
7351 CTTGACCTAC CTCAGATCAT TCAACGACTC CATGGCCTTA GCGCATTTTC
7401 ACTCCATAGT TACTCTCCAG GTGAGATCAA TAGGGTGGCT TCATGCCTCA
7451 GGAAACTTGG GGTACCGCCC TTGCGAGTCT GGAGACATCG GGCCAGAAGT
7501 GTCCGCGCTA GGCTACTGTC CCAGGGGGGG AGGGCTGCCA CTTGTGGCAA
7551 GTACCTCTTC AACTGGGCAG TAAGGACCAA GCTCAAATC ACTCCAATCC
7601 CGGCTGCGTC CCAGTTGGAT TTATCCAGCT GGTTCGTTGC TGTTACAGC
7651 GGGGAGACA TATATCACAG CCTGTCTCGT GCGGACCCC GCTGGTTCAT
7701 GTGGTGCCTA CTCCTACTTT CTGTAGGGGT AGGCATCTAT CTACTCCCCA

FIG. 1E

7751 ACCGATGAAC GGGGAGCTAA ACACTCCAGG CCAATAGGCC ATCCTGTTTT
7801 TTTCCTTTT TTTTTTCTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT
7851 TTCTCCTTTT TTTTTCCTCT TTTTTCCTT TTCTTTCCTT TGGTGGCTCC
7901 ATCTTAGCCC TAGTCACGGC TAGCTGTGAA AGGTCCGTGA GCCGCTTGAC
7951 TGCAGAGAGT GCTGATACTG GCCTCTCTGC AGATCAAGTA CTTCTAGAGA
8001 ATTCTAGCTT GGCCTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT
8051 TATCAGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTAA
8101 AGCCTGGGAT GCCTAATGAG TGAGCTAACT CACATTAGTT GCGTTGCGCT
8151 CACTGCCCCG TTTCCAGTCG GGAAACCTGT CGTGCCAGCT CCATTAGTGA
8201 ATCGTCCAAC GCACGGGGAG AGGCGGTTTG CGTATTGGGC GCAC'TCCGC
8251 TTCTCGCTC ACTGACTCGC TGCCTCGTT CGTTCGGCTG CGGCGAGCCG
8301 TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT
8351 AACGCAGGAA AGACCATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG
8401 TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG
8451 AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA
8501 CTATAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TCGCTCTCC
8551 TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG
8601 GAAGCGTGGC GCTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG
8651 TAGGTCGTTT GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC
8701 CGACCGCTGC GCCTTATCCG GTAACATATCG TCTTGAGTCC AACCCGGTAA
8751 GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA
8801 GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAAC TA
8851 CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG
8901 TTACCTTCGG AAAAAGAGTT GGTAAGTCTT GATCCGGCAA ACAAACCACC
8951 GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA
9001 AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC
9051 AGTGGAACGA AAATCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA
9101 AGGATCTTCA CCTAGATCCT TTAAATTAA AAATGAAGTT TTAAATCAAT
9151 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA
9201 GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTTATC CATAGTTGCC
9251 TGAATCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG

FIG. 1F

9301 CCCCAGTGCT GCAATGATAC CGCGAGAACC ACGCTCACCC GCACCAGATT
9351 TATCAGCAAT AAACCAGCCA GCCGGAAGTG CGCTGCGGAG AAGTGGTCCT
9401 GCAACTTTAT CCGCCTCCAT CCAGTCTATT AGTTGTTGCC GGAAGCTAG
9451 AGTAAGTAGT TCGCCAGTCA GCAGTTTGCG TAACGTCGTT GCCATAGCAA
9501 CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC
9551 GGCTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAA
9601 AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG
9651 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC
9701 ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC
9751 ATTCTGAGAA TAGTGTATGC GCGGACCGAG TTGCTCTTGC CCGGCGTCAA
9801 TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAGT GCTCATCATT
9851 GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG
9901 ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT
9951 TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC
10001 GCAAAAAGG GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT
10051 CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG
10101 GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC
10151 ACATTTCCCC GAAAAGTGCC ACCTGACGTC TAAGAAACCA TTATTACCAT
10201 GACATTAACC TATAAAAATA GCGTATCAC GAAGCCCTTT CGTCTAGCGC
10251 GTTTCGGTGA TGACGGTGAA AACCTCTGAC ACTTGCAGCT CCCGCAGACG
10301 GTCACAGCTT GTCTGTAAGC GGATGCCGGG AGCAGGCAAG CCCGTCAGGG
10351 CGCGTCAGTG GGTGTTGCGG GGTGTCGGGG CTGGCTTAAC TATGCGGCAT
10401 CAGAGCAGAT TGTAAGTACA GTACACCAGA TCGGGTGTGA AATACCGCAC
10451 AGATGCGTAA GGAGAAAATA CCGCATCAGC CTCCATTCGC CATTAGACT
10501 CCGCAACTGT TGGGAAGGGC GGTCAGTACG CGCTTCTTCG CTATTACGCC
10551 AACTGGCGAA AGGGGGATGT GCTGCAAGGC GATTAAGTTG GGTAACGCCA
10601 GGGTTTTCCC AATCACGACG TTGTAAAACG ACAGCCAATG AATTGAAGCT
10651 TATTAATTCT AGACTGAAGC TTTTAATACG ACTCACTATA (SEQ. ID. NO.:3)

Fig. 1G

SEQUENCE LISTING

<110> Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.

<120> HEPATITIS C VIRUS REPLICONS AND REPLICON
ENHANCED CELLS

<130> IT0003 PCT

<150> 60/263,479

<151> 2001-01-23

<160> 13

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 3010

<212> PRT

<213> Con 1 HCV isolate nucleic acid

<400> 1

```

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn
 1          5          10          15
Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly
      20          25          30
Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala
      35          40          45
Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro
      50          55          60
Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly
65          70          75          80
Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp
      85          90          95
Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro
      100          105          110
Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys
      115          120          125
Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu
      130          135          140
Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp
145          150          155          160
Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile
      165          170          175
Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr
      180          185          190
Glu Val Arg Asn Val Ser Gly Val Tyr His Val Thr Asn Asp Cys Ser
      195          200          205
Asn Ala Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro
      210          215          220
Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val
225          230          235          240
Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr
      245          250          255
Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Leu Cys
      260          265          270
Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ala
      275          280          285
Gln Leu Phe Thr Phe Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys
      290          295          300
Asn Cys Ser Ile Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp
305          310          315          320

```


Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ser Gln
 325 330 335
 Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His
 340 345 350
 Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp
 355 360 365
 Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Gly
 370 375 380
 Thr Tyr Val Thr Gly Gly Thr Met Ala Lys Asn Thr Leu Gly Ile Thr
 385 390 395 400
 Ser Leu Phe Ser Pro Gly Ser Ser Gln Lys Ile Gln Leu Val Asn Thr
 405 410 415
 Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser
 420 425 430
 Leu Asn Thr Gly Phe Leu Ala Ala Leu Phe Tyr Val His Lys Phe Asn
 435 440 445
 Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys Ser Pro Ile Asp Ala
 450 455 460
 Phe Ala Gln Gly Trp Gly Pro Ile Thr Tyr Asn Glu Ser His Ser Ser
 465 470 475 480
 Asp Gln Arg Pro Tyr Cys Trp His Tyr Ala Pro Arg Pro Cys Gly Ile
 485 490 495
 Val Pro Ala Ala Gln Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser
 500 505 510
 Pro Val Val Val Gly Thr Thr Asp Arg Phe Gly Val Pro Thr Tyr Ser
 515 520 525
 Trp Gly Glu Asn Glu Thr Asp Val Leu Leu Leu Asn Asn Thr Arg Pro
 530 535 540
 Pro Gln Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe
 545 550 555 560
 Thr Lys Thr Cys Gly Gly Pro Pro Cys Asn Ile Gly Gly Ile Gly Asn
 565 570 575
 Lys Thr Leu Thr Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu Ala
 580 585 590
 Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp Leu Thr Pro Arg Cys Leu
 595 600 605
 Val His Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Val Asn Phe
 610 615 620
 Thr Ile Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg Leu
 625 630 635 640
 Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asn Leu Glu Asp
 645 650 655
 Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Glu Trp
 660 665 670
 Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr Gly
 675 680 685
 Leu Ile His Leu His Gln Asn Val Val Asp Val Gln Tyr Leu Tyr Gly
 690 695 700
 Ile Gly Ser Ala Val Val Ser Phe Ala Ile Lys Trp Glu Tyr Val Leu
 705 710 715 720
 Leu Leu Phe Leu Leu Ala Asp Ala Arg Val Cys Ala Cys Leu Trp
 725 730 735
 Met Met Leu Leu Ile Ala Gln Ala Glu Ala Ala Leu Glu Asn Leu Val
 740 745 750
 Val Leu Asn Ala Ala Ser Val Ala Gly Ala His Gly Ile Leu Ser Phe
 755 760 765
 Leu Val Phe Phe Cys Ala Ala Trp Tyr Ile Lys Gly Arg Leu Val Pro
 770 775 780
 Gly Ala Ala Tyr Ala Leu Tyr Gly Val Trp Pro Leu Leu Leu Leu Leu
 785 790 795 800
 Leu Ala Leu Pro Pro Arg Ala Tyr Ala Met Asp Arg Glu Met Ala Ala
 805 810 815

Ser Cys Gly Gly Ala Val Phe Val Gly Leu Ile Leu Leu Thr Leu Ser
 820 825 830
 Pro His Tyr Lys Leu Phe Leu Ala Arg Leu Ile Trp Trp Leu Gln Tyr
 835 840 845
 Phe Ile Thr Arg Ala Glu Ala His Leu Gln Val Trp Ile Pro Pro Leu
 850 855 860
 Asn Val Arg Gly Gly Arg Asp Ala Val Ile Leu Leu Thr Cys Ala Ile
 865 870 875 880
 His Pro Glu Leu Ile Phe Thr Ile Thr Lys Ile Leu Leu Ala Ile Leu
 885 890 895
 Gly Pro Leu Met Val Leu Gln Ala Gly Ile Thr Lys Val Pro Tyr Phe
 900 905 910
 Val Arg Ala His Gly Leu Ile Arg Ala Cys Met Leu Val Arg Lys Val
 915 920 925
 Ala Gly Gly His Tyr Val Gln Met Ala Leu Met Lys Leu Ala Ala Leu
 930 935 940
 Thr Gly Thr Tyr Val Tyr Asp His Leu Thr Pro Leu Arg Asp Trp Ala
 945 950 955 960
 His Ala Gly Leu Arg Asp Leu Ala Val Ala Val Glu Pro Val Val Phe
 965 970 975
 Ser Asp Met Glu Thr Lys Val Ile Thr Trp Gly Ala Asp Thr Ala Ala
 980 985 990
 Cys Gly Asp Ile Ile Leu Gly Leu Pro Val Ser Ala Arg Arg Gly Arg
 995 1000 1005
 Glu Ile His Leu Gly Pro Ala Asp Ser Leu Glu Gly Gln Gly Trp Arg
 1010 1015 1020
 Leu Leu Ala Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu
 1025 1030 1035 1040
 Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Arg Asn Gln Val Glu
 1045 1050 1055
 Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr
 1060 1065 1070
 Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys
 1075 1080 1085
 Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val
 1090 1095 1100
 Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu
 1105 1110 1115 1120
 Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
 1125 1130 1135
 Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu
 1140 1145 1150
 Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro
 1155 1160 1165
 Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val
 1170 1175 1180
 Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser
 1185 1190 1195 1200
 Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro
 1205 1210 1215
 Pro Ala Val Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr
 1220 1225 1230
 Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly
 1235 1240 1245
 Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe
 1250 1255 1260
 Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr
 1265 1270 1275 1280
 Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr
 1285 1290 1295
 Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile
 1300 1305 1310

Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly
 1315 1320 1325
 Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val
 1330 1335 1340
 Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro
 1345 1350 1355 1360
 Asn Ile Glu Glu Val Ala Leu Ser Ser Thr Gly Glu Ile Pro Phe Tyr
 1365 1370 1375
 Gly Lys Ala Ile Pro Ile Glu Thr Ile Lys Gly Gly Arg His Leu Ile
 1380 1385 1390
 Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser
 1395 1400 1405
 Gly Leu Gly Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser
 1410 1415 1420
 Val Ile Pro Thr Ser Gly Asp Val Ile Val Val Ala Thr Asp Ala Leu
 1425 1430 1435 1440
 Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr
 1445 1450 1455
 Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile
 1460 1465 1470
 Glu Thr Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg
 1475 1480 1485
 Gly Arg Thr Gly Arg Gly Arg Met Gly Ile Tyr Arg Phe Val Thr Pro
 1490 1495 1500
 Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys
 1505 1510 1515 1520
 Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser
 1525 1530 1535
 Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln
 1540 1545 1550
 Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile
 1555 1560 1565
 Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro
 1570 1575 1580
 Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro
 1585 1590 1595 1600
 Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro
 1605 1610 1615
 Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln
 1620 1625 1630
 Asn Glu Val Thr Thr Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys
 1635 1640 1645
 Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu Val Gly
 1650 1655 1660
 Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Thr Thr Gly Ser Val
 1665 1670 1675 1680
 Val Ile Val Gly Arg Ile Ile Leu Ser Gly Lys Pro Ala Ile Ile Pro
 1685 1690 1695
 Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu Glu Cys Ala
 1700 1705 1710
 Ser His Leu Pro Tyr Ile Glu Gln Gly Met Gln Leu Ala Glu Gln Phe
 1715 1720 1725
 Lys Gln Lys Ala Ile Gly Leu Leu Gln Thr Ala Thr Lys Gln Ala Glu
 1730 1735 1740
 Ala Ala Ala Pro Val Val Glu Ser Lys Trp Arg Thr Leu Glu Ala Phe
 1745 1750 1755 1760
 Trp Ala Lys His Met Trp Asn Phe Ile Ser Gly Ile Gln Tyr Leu Ala
 1765 1770 1775
 Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala Ile Ala Ser Leu Met Ala
 1780 1785 1790
 Phe Thr Ala Ser Ile Thr Ser Pro Leu Thr Thr Gln His Thr Leu Leu
 1795 1800 1805

Phe Asn Ile Leu Gly Gly Trp Val Ala Ala Gln Leu Ala Pro Pro Ser
 1810 1815 1820
 Ala Ala Ser Ala Phe Val Gly Ala Gly Ile Ala Gly Ala Ala Val Gly
 1825 1830 1835 1840
 Ser Ile Gly Leu Gly Lys Val Leu Val Asp Ile Leu Ala Gly Tyr Gly
 1845 1850 1855
 Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys Val Met Ser Gly Glu
 1860 1865 1870
 Met Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro Ala Ile Leu Ser
 1875 1880 1885
 Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala Ile Leu Arg Arg
 1890 1895 1900
 His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met Asn Arg Leu Ile
 1905 1910 1915 1920
 Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Thr His Tyr Val Pro
 1925 1930 1935
 Glu Ser Asp Ala Ala Ala Arg Val Thr Gln Ile Leu Ser Ser Leu Thr
 1940 1945 1950
 Ile Thr Gln Leu Leu Lys Arg Leu His Gln Trp Ile Asn Glu Asp Cys
 1955 1960 1965
 Ser Thr Pro Cys Ser Gly Ser Trp Leu Arg Asp Val Trp Asp Trp Ile
 1970 1975 1980
 Cys Thr Val Leu Thr Asp Phe Lys Thr Trp Leu Gln Ser Lys Leu Leu
 1985 1990 1995 2000
 Pro Arg Leu Pro Gly Val Pro Phe Phe Ser Cys Gln Arg Gly Tyr Lys
 2005 2010 2015
 Gly Val Trp Arg Gly Asp Gly Ile Met Gln Thr Thr Cys Pro Cys Gly
 2020 2025 2030
 Ala Gln Ile Thr Gly His Val Lys Asn Gly Ser Met Arg Ile Val Gly
 2035 2040 2045
 Pro Arg Thr Cys Ser Asn Thr Trp His Gly Thr Phe Pro Ile Asn Ala
 2050 2055 2060
 Tyr Thr Thr Gly Pro Cys Thr Pro Ser Pro Ala Pro Asn Tyr Ser Arg
 2065 2070 2075 2080
 Ala Leu Trp Arg Val Ala Ala Glu Glu Tyr Val Glu Val Thr Arg Val
 2085 2090 2095
 Gly Asp Phe His Tyr Val Thr Gly Met Thr Thr Asp Asn Val Lys Cys
 2100 2105 2110
 Pro Cys Gln Val Pro Ala Pro Glu Phe Phe Thr Glu Val Asp Gly Val
 2115 2120 2125
 Arg Leu His Arg Tyr Ala Pro Ala Cys Lys Pro Leu Leu Arg Glu Glu
 2130 2135 2140
 Val Thr Phe Leu Val Gly Leu Asn Gln Tyr Leu Val Gly Ser Gln Leu
 2145 2150 2155 2160
 Pro Cys Glu Pro Glu Pro Asp Val Ala Val Leu Thr Ser Met Leu Thr
 2165 2170 2175
 Asp Pro Ser His Ile Thr Ala Glu Thr Ala Lys Arg Arg Leu Ala Arg
 2180 2185 2190
 Gly Ser Pro Pro Ser Leu Ala Ser Ser Ser Ala Ser Gln Leu Ser Ala
 2195 2200 2205
 Pro Ser Leu Lys Ala Thr Cys Thr Thr Arg His Asp Ser Pro Asp Ala
 2210 2215 2220
 Asp Leu Ile Glu Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn
 2225 2230 2235 2240
 Ile Thr Arg Val Glu Ser Glu Asn Lys Val Val Ile Leu Asp Ser Phe
 2245 2250 2255
 Glu Pro Leu Gln Ala Glu Glu Asp Glu Arg Glu Val Ser Val Pro Ala
 2260 2265 2270
 Glu Ile Leu Arg Arg Ser Arg Lys Phe Pro Arg Ala Met Pro Ile Trp
 2275 2280 2285
 Ala Arg Pro Asp Tyr Asn Pro Pro Leu Leu Glu Ser Trp Lys Asp Pro
 2290 2295 2300

Asp Tyr Val Pro Pro Val Val His Gly Cys Pro Leu Pro Pro Ala Lys
 2305 2310 2315 2320
 Ala Pro Pro Ile Pro Pro Pro Arg Arg Lys Arg Thr Val Val Leu Ser
 2325 2330 2335
 Glu Ser Thr Val Ser Ser Ala Leu Ala Glu Leu Ala Thr Lys Thr Phe
 2340 2345 2350
 Gly Ser Ser Glu Ser Ser Ala Val Asp Ser Gly Thr Ala Thr Ala Ser
 2355 2360 2365
 Pro Asp Gln Pro Ser Asp Asp Gly Asp Ala Gly Ser Asp Val Glu Ser
 2370 2375 2380
 Tyr Ser Ser Met Pro Pro Leu Glu Gly Glu Pro Gly Asp Pro Asp Leu
 2385 2390 2395 2400
 Ser Asp Gly Ser Trp Ser Thr Val Ser Glu Glu Ala Ser Glu Asp Val
 2405 2410 2415
 Val Cys Cys Ser Met Ser Tyr Thr Trp Thr Gly Ala Leu Ile Thr Pro
 2420 2425 2430
 Cys Ala Ala Glu Glu Thr Lys Leu Pro Ile Asn Ala Leu Ser Asn Ser
 2435 2440 2445
 Leu Leu Arg His His Asn Leu Val Tyr Ala Thr Thr Ser Arg Ser Ala
 2450 2455 2460
 Ser Leu Arg Gln Lys Lys Val Thr Phe Asp Arg Leu Gln Val Leu Asp
 2465 2470 2475 2480
 Asp His Tyr Arg Asp Val Leu Lys Glu Met Lys Ala Lys Ala Ser Thr
 2485 2490 2495
 Val Lys Ala Lys Leu Leu Ser Val Glu Glu Ala Cys Lys Leu Thr Pro
 2500 2505 2510
 Pro His Ser Ala Arg Ser Lys Phe Gly Tyr Gly Ala Lys Asp Val Arg
 2515 2520 2525
 Asn Leu Ser Ser Lys Ala Val Asn His Ile Arg Ser Val Trp Lys Asp
 2530 2535 2540
 Leu Leu Glu Asp Thr Glu Thr Pro Ile Asp Thr Thr Ile Met Ala Lys
 2545 2550 2555 2560
 Asn Glu Val Phe Cys Val Gln Pro Glu Lys Gly Gly Arg Lys Pro Ala
 2565 2570 2575
 Arg Leu Ile Val Phe Pro Asp Leu Gly Val Arg Val Cys Glu Lys Met
 2580 2585 2590
 Ala Leu Tyr Asp Val Val Ser Thr Leu Pro Gln Ala Val Met Gly Ser
 2595 2600 2605
 Ser Tyr Gly Phe Gln Tyr Ser Pro Gly Gln Arg Val Glu Phe Leu Val
 2610 2615 2620
 Asn Ala Trp Lys Ala Lys Lys Cys Pro Met Gly Phe Ala Tyr Asp Thr
 2625 2630 2635 2640
 Arg Cys Phe Asp Ser Thr Val Thr Glu Asn Asp Ile Arg Val Glu Glu
 2645 2650 2655
 Ser Ile Tyr Gln Cys Cys Asp Leu Ala Pro Glu Ala Arg Gln Ala Ile
 2660 2665 2670
 Arg Ser Leu Thr Glu Arg Leu Tyr Ile Gly Gly Pro Leu Thr Asn Ser
 2675 2680 2685
 Lys Gly Gln Asn Cys Gly Tyr Arg Arg Cys Arg Ala Ser Gly Val Leu
 2690 2695 2700
 Thr Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr Leu Lys Ala Ala Ala
 2705 2710 2715 2720
 Ala Cys Arg Ala Ala Lys Leu Gln Asp Cys Thr Met Leu Val Cys Gly
 2725 2730 2735
 Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly Thr Gln Glu Asp Glu
 2740 2745 2750
 Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala Pro
 2755 2760 2765
 Pro Gly Asp Pro Pro Lys Pro Glu Tyr Asp Leu Glu Leu Ile Thr Ser
 2770 2775 2780
 Cys Ser Ser Asn Val Ser Val Ala His Asp Ala Ser Gly Lys Arg Val
 2785 2790 2795 2800

```
<210> 2
<211> 9605
<212> DNA
<213> Con 1 HCV isolate amino acid
```

<400> 2						
gccagccccc	gattgggggc	gacactccac	catagatcac	tcccctgtga	ggaactactg	60
tcttcacgca	gaaagcgtct	agccatggcg	ttagtatgag	tgtcgtgcag	cctccaggac	120
ccccctcccc	gggagagcca	tagtggctctg	cggaaacggg	gagtaacacg	gaattgccag	180
gacgaccggg	tccctttcttg	gatcaacccg	ctcaattgct	ggagatttgg	gcgtgcccc	240
gcgagactgc	tagccgagta	gtgttgggtc	gcgaaaggcg	ttgtgggtact	gcctgatagg	300
gtgcttgcca	gtgccccggg	aggtctcgta	gaccgtgcac	catgagcacg	aatccctaac	360
ctcaagaaaa	aaccaaacgt	aaccaacaac	gccgccaca	ggacgtcaag	ttcccgggcg	420
gtggtcagat	cgtcggtgga	gtttacctgt	tgcgcgcag	gggcccagg	ttgggtgtgc	480
gcgcgactag	gaagacttcc	gagcggtcgc	aacctcgtgg	aaggcgacaa	cctatcccca	540
aggctcgcca	gccccagggt	agggcctggg	ctcagcccgg	gtaccctgtg	ccccctctatg	600
gcaatgaggg	cttgggggtg	cgaggatggc	tctgttcaac	ccgtggctct	ggccttagtt	660
ggggccccc	ggacccccgg	cgtaggtcgc	gcaatttggg	taaggtcata	gataccctca	720
cgtgcggctt	cgccgacttc	atggggtaca	ttccgctcgt	cggcgcccc	ctagggggcg	780
ctgccagggt	cctgggcgat	ggcgctccgg	ttctggagga	cggcgtgaac	tatgcaacag	840
ggaatctgcc	cgggtgtctc	ttttctatct	tctctttggc	tttgcgtgcc	tgtttgacca	900
tcccagcttc	cgcttatgaa	gtgcgcaacg	tatccggagt	gtaccatgtc	acgaacgact	960
gctccaacgt	aagcattgtg	tatgaggcag	cggacatgat	catgcatacc	cccgggtgcg	1020
tgccctgcgt	tcgggagaac	aactctctcc	gctgctgggt	agcgtctcact	cccagctctg	1080
cggccaggaa	cgctagcgtc	cccactacga	cgtacagacg	ccatgtcgat	ttgctcgttg	1140
gggcggtctg	tctctgctcc	gctatgtacg	tgggagatct	ctgcggatct	gttttctctg	1200
tcgcccagct	gttcaacctc	tcgcctcgcc	ggcacgagac	agtacaggac	tgcaattgct	1260
caatatatcc	cgcccacgtg	acaggctcac	gtatggcttg	ggatatgagt	atgaactggg	1320
cacctatacg	agccctagt	gtatcgcagt	tactccggat	ccacaagct	gtcgtggata	1380
tggtggcggg	ggcccatctg	ggagtcctag	cgggccttgc	ctactattcc	atggtgggga	1440
actgggctaa	ggtttctgatt	gtgatgtcat	tctttgcccg	cgttgacggg	ggaacctatg	1500
tgacaggggg	gacgattggc	aaaaaacacc	tcgggattac	gtccctcttt	tcacccgggt	1560
catcccagaa	aatccagctt	gtaaacacca	acggcagctg	gcacatcaac	aggactggcc	1620

tgaactgcaa	tgactccctc	aacactgggt	tccttgctgc	gctgttctac	gtgcacaagt	1680
tcaactcacc	tggatgcca	gagcgcatgg	ccagctgcag	ccccatcgac	gcgttcgctc	1740
aggggtgggg	gccccact	tacaatgagt	cacacagctc	ggaccagagg	ccttattggt	1800
ggcactacgc	accccgccg	tgcggtatcg	taccgcggc	gcaggtgtgt	ggtccagtgt	1860
actgcttcac	cccaagccct	gtcgtggtgg	ggacgaccga	ccggttcggc	gtccctacgt	1920
acagttgggg	ggagaatgag	acggacgtgc	tgcttcttaa	caacacgcgg	ccgccgcaag	1980
gcaactgggt	tggctgtaca	tggatgaata	gcactgggtt	caccaagacg	tgcgggggcc	2040
ccccgtgtaa	catcgggggg	atcggaata	aaaccttgac	ctgccccacg	gactgcttcc	2100
ggaagcacc	cgaggccact	tacaccaagt	gtggttcggg	gccttggttg	acaccagat	2160
gcttggtcca	ctaccatac	aggctttggc	actaccctg	cactgtcaac	tttaccatct	2220
tcaaggttag	gatgtacgtg	gggggagtgg	agcacaggct	cgaagccgca	tgcaattgga	2280
ctcgaggaga	gcgttgtaac	ctggaggaca	gggacagatc	agagcttagc	ccgctgtctg	2340
tgtctacaac	ggagtggcag	gtattgccct	gttccttcac	caccctaccg	gctctgtcca	2400
ctggtttgat	ccatctccat	cagaacgtcg	tggacgtaca	atacctgtac	ggtatagggt	2460
cggcggttgt	ctcctttgca	atcaaatggg	agtatgtcct	gttgctcttc	cttcttctgg	2520
cggacgcgcg	cgtctgtgcc	tgcttgtgga	tgatgtgctg	gatagctcaa	gctgaggccg	2580
ccctagagaa	cctggtggtc	ctcaacgcgg	catcctgggc	cggggcgcac	ggcattctct	2640
ccttcctcgt	gttcttctgt	gctgcctggt	acatcaagg	caggctggtc	cctggggcgg	2700
catatgccct	ctacggcgta	tggccgctac	tcctgctcct	gctggcggtta	ccaccacgag	2760
catacgccat	ggaccgggag	atggcagcat	ctcgtcgagg	cgcggttttc	gtaggtctga	2820
tactcttgac	cttgtcaccg	cactataagc	tgctcctcgc	taggctcata	tggtggttac	2880
aatattttat	caccagggcc	gaggcacact	tgcaagtgtg	gatccccccc	ctcaacgttc	2940
ggggggggccg	cgatgccgtc	atcctcctca	cgtgcgcgat	ccaccagag	ctaattctta	3000
ccatcaccaa	aatcttgcct	gccatactcg	gtcactcat	ggtgtctcag	gctggtataa	3060
caaagtgcc	gtacttcgtg	cgcgcacacg	ggctcatctg	tgcatgcatg	ctggtgcgga	3120
aggttgctgg	gggtcattat	gtccaaatgg	ctctcatgaa	gttgcccgca	ctgacaggta	3180
cgtacgttta	tgaccatctc	acccccactgc	gggactgggc	ccacgcgggc	ctacgagacc	3240
ttgctgggtg	agttgagccc	gtcgtcttct	ctgatattgga	gaccaagggt	atcacctggg	3300
gggcagacac	cgcggcgtgt	ggggacatca	tcttgggcct	gcccgtctcc	gcccgcaggg	3360
ggagggagat	acatctggga	ccggcagaca	gccttgaagg	gcaggggtgg	cgactcctcg	3420
gcctattac	ggcctactcc	caacagacgc	gaggcctact	tggctgcatc	atcactagcc	3480
tcacaggccg	ggacaggaac	caggtcgagg	gggaggtcca	agtgtctctc	accgcaacac	3540
aatctttcct	ggcgacctgc	gtcaatggcg	tgtgttggac	tgtctatcat	ggtgcccgtc	3600
caaagaccct	tgccggccca	aaggggccaa	tcacccaaat	gtacaccaat	gtggaccagg	3660
acctcgctcg	ctggcaagcg	ccccccgggg	cgcgttcctt	gacacatgc	acctgcggca	3720
gctcggtacc	ttacttggtc	acgaggcgat	ccgatgtcat	tccggtgcgc	cgccggggcg	3780
acagcagggg	gagcctactc	tccccaggc	ccgtctccta	cttgaagggc	tcttcggggc	3840
gtccactgct	ctgcccctcg	gggcacgctg	tgggcatctt	tccggctgcc	gtgtgcaccc	3900
gaggggttgc	gaaggcggtg	gactttgtac	ccgtcgagtc	tatggaaacc	actatgcggt	3960
ccccgtctct	cacggacaac	tcgtccctc	cggcgtacc	gcagacattc	caggtggccc	4020
atctacacgc	ccctactggt	agcggcaaga	gtcacaaggt	gcccgtctcg	tatgcagccc	4080
aagggtataa	ggtgcttgtc	ctgaacccgt	ccgtcgccgc	caccctaggt	ttcggggcgt	4140
atatgtctaa	ggcacatggt	atcgacccta	acatcagaac	cggggtaagg	accatcacca	4200
cgggtgcccc	catcacgtac	tccacctatg	gcaagtttct	tgccgacggt	ggttgctctg	4260
ggggcgcccta	tgacatcata	atatgtgatg	agtgtccact	aactgactcg	accactatcc	4320
tgggcatcgg	cacagtcctg	gaccaagcgg	agacggctgg	agcgcgactc	gtcgtgctcg	4380
ccaccgtac	gcctccggga	tcggtcaccg	tgccacatcc	aaacatcgag	gaggtggctc	4440
tgtccagcac	tggagaaatc	cccttttatg	gcaaagccat	ccccatcgag	accatcaagg	4500
gggggaggca	cctcattttc	tgccattcca	agaagaaatg	tgatgagctc	gccgcgaagc	4560
tgtccggcct	cggactcaat	gctgtagcat	attaccgggg	ccttgatgta	tccgtcatac	4620
caactagcgg	agacgtcatt	gtcgtagcaa	cggacgtctc	aatgacgggc	tttaccggcg	4680
atctcgactc	agtgatcgac	tgcaatacat	gtgtcaccca	gacagtcgac	ttcagcctgg	4740
acccgacctt	caccattgag	acgacgaccg	tgccacaaga	cgcggtgtca	cgctcgagc	4800
ggcgaggcag	gactggtagg	ggcaggatgg	gcattttacag	gtttgtgact	ccaggagaac	4860
ggccctcggg	catgttccat	tcctcggttc	tgtgcgagtg	ctatgacgcg	ggctgtgctt	4920
ggtacgagct	cacgcccccc	gagacctcag	ttaggttgcg	ggcttaccta	aacacaccag	4980
ggttcgccgt	ctgccaggac	catctggagt	cttgggagag	cgtctttaca	ggcctcacc	5040
acatagacgc	ccatttcttg	tcccagacta	agcaggcagg	agacaacttc	ccctacctgg	5100
tagcatacca	ggctacggtg	tgcgccaggg	ctcaggctcc	acctccatcg	tgggacccaa	5160
tgtggaagtg	tctcatacgg	ctaaagccta	cgtgcacagg	gccaacgccc	ctgctgtata	5220
ggctgggagc	gcttcaaaac	gaggttacta	ccacacacc	cataacccaa	tacatcatgg	5280
catgcatgtc	ggctgacctg	gaggtcgtca	cgagcacttg	ggtgctggta	ggcggagtc	5340

tagcagctct	ggccgcgtat	tgcctgacaa	caggcagcgt	ggtcattgtg	ggcaggatca	5400
tcttgcccg	aaagccggcc	atcattcccg	acagggaggt	cctttaccgg	gagttcgatg	5460
agatggaaga	gtgcgcctca	cacctccctt	acatcgaaca	gggaatgcag	ctcgccgaac	5520
aattcaaaca	gaaggcaatc	gggttgctgc	aaacagccac	caagcaagcg	gaggctgctg	5580
ctcccgtggt	ggaatccaag	tggcggaccc	tcgaagcctt	ctgggcgaag	catatgtgga	5640
atttcacacg	cgggatacaa	tatttagcag	gcttgccac	tctgcctggc	aaccccgcca	5700
tagcatcact	gatggcattc	acagcctcta	tcaccagccc	gctcaccacc	caacataccc	5760
tctgttttaa	catcctgggg	ggatgggtgg	ccgcccaact	tgctcctccc	agcgtgctt	5820
ctgctttcgt	aggcgccggc	atcgtctggag	cggctgttgg	cagcataggc	cttggaagg	5880
tgcttggtga	tattttggca	ggttatggag	caggggtggc	aggcgcgctc	gtggccttta	5940
aggtcatgag	cggcgagatg	ccctccaccg	aggacctggt	taacctactc	cctgctatcc	6000
tctcccttgg	cgccctagtc	gtcggggtcg	tgtgcgcagc	gatactgcgt	cggcacgtgg	6060
gcccagggga	gggggctgtg	cagtggatga	accggtgat	agcgttcgct	tcgcggggta	6120
accacgtctc	ccccacgcac	tatgtgcctg	agagcgacgc	tgcagcacgt	gtcactcaga	6180
tctctctag	tcttaccatc	actcagctgc	tgaagaggct	tcaccagtgg	atcaacgagg	6240
actgctccac	gccatgctcc	ggctcgtggc	taagagatgt	ttgggattgg	atatgcacgg	6300
tggtgactga	tttcaagacc	tggctccagt	ccaagctcct	gccgcgattg	cggggagtcc	6360
ccttcttctc	atgtcaacgt	gggtacaagg	gagtctggcg	gggcgacggc	atcatgcaaa	6420
ccacctgccc	atgtggagca	cagatcaccg	gacatgtgaa	aaacgggttc	atgaggatcg	6480
tggggcctcg	gacctgtagt	aacacgtggc	atggaacatt	ccccattaac	gcgtacacca	6540
cgggccccctg	cacgccttcc	ccggcgccaa	attattctag	ggcgctgtgg	cgggtggctg	6600
ctgaggagta	cgtggaggtt	acgcgggtgg	gggatttcca	ctacgtgacg	ggcatgacca	6660
ctgacaacgt	aaagtgcctg	tgtcaggttc	cggcccccca	attcttcaca	gaagtggatg	6720
gggtgcggtt	gcacaggtac	gctccagcat	gcaaacccct	cctacgggag	gaggtcacat	6780
tcttggtcgg	gctcaatcaa	tacctggttg	ggtcacagct	cccatgcgag	cccgaaccgg	6840
acgtagcagt	gctcacttcc	atgctcaccg	acccttccca	cattacggcg	gagacggcta	6900
agcgtaggct	ggccagggga	tctccccctt	ccttgccag	ctcatcagct	agccagctgt	6960
ctgcgccttc	cttgaaggca	acatgcacta	cccgctatga	ctccccggac	gctgacctca	7020
tcgaggccaa	cctcctgtgg	cggcaggaga	tgggcgggaa	catcacccgc	gtggagttag	7080
aaaataaggt	agtaattttg	gactctttcg	agccgctcca	agcggaggag	gatgagaggg	7140
aagtatccgt	tccggcggag	atcctgcgga	ggtccaggaa	attccctcga	gcgatgcccc	7200
tatgggcacg	cccgagttac	aaccttccac	tgttagagtc	ctggaaggac	ccggactacg	7260
tccctccagt	ggtaacacgg	tgtccattgc	cgcctgccaa	ggccccctcg	ataccacctc	7320
cacggaggaa	gaggacggtt	gtcctgtcag	aatctaccgt	gtcttctgcc	ttggcggagc	7380
tcgccacaaa	gaccttcggc	agctccgaat	cgtcggccgt	cgacagcggc	acggcaaccg	7440
cctctcctgc	gacccctcc	gacgacggcg	acgcgggatc	cgacgttgag	tcgtactcct	7500
ccatgcccc	ccttgagggg	gagccggggg	atccccgatc	cagcgacggg	tcttggtcta	7560
ccgtaagcga	ggaggctagt	gaggacgtcg	tctgctgctc	gatgtcctac	acatggacag	7620
gcgccccgat	cacgccatgc	gctgcggagg	aaaccaagct	gccccatcaat	gcactgagca	7680
actcttctgt	ccgtcaccac	aacttggctc	atgtctaac	atctcgcagc	gcaagcctgc	7740
ggcagaagaa	ggctaccttt	gacagatgc	aggctctgga	cgaccactac	cgggacgtgc	7800
tcaaggagat	gaaggcgaag	gcgtccacag	ttaaggctaa	acttctatcc	gtggagggaag	7860
cctgtaagct	gacgccccca	cattcggcca	gatctaaatt	tggctatggg	gcaaaaggacg	7920
tccggaacct	atccagcaag	gcccgttaacc	acatccgctc	cgtgtggaag	gacttgctgg	7980
aagacactga	gacaccaatt	gacaccacca	tcattggcaaa	aaatgaggtt	ttctgcgtcc	8040
aaccagagaa	ggggggccgc	aagccagctc	gccttatcgt	attcccagat	ttgggggttc	8100
gtgtgtgcga	gaaaatggcc	ctttacgatg	tggcttccac	cctccctcag	gccgtgatgg	8160
gctcttcata	cggattccaa	tactctcctg	gacagcgggt	cgagtctctg	gtgaatgcct	8220
ggaaagcgaa	gaaatgccct	atgggcttcg	catatgacac	ccgctgtttt	gactcaacgg	8280
tactgagaa	tgacatccgt	gttgaggagt	caatctacca	atgttgtagc	ttggcccccg	8340
aagccagaca	ggccataagg	tcgtctacag	agcggcttta	catcgggggc	cccctgacta	8400
attctaaagg	gcagaactgc	ggctatcgcc	ggcgccgcgc	gagcgggtga	ctgacgacca	8460
gctgcggtaa	tacctcaca	tgttacttga	aggcgcgtgc	ggcctgtcga	gctgcgaagc	8520
tccaggactg	cacgatgtc	gtatgcggag	acgaccttgt	cgttatctgt	gaaagcgcgg	8580
ggaccaaga	ggacgaggcg	agcctacggg	ccttcacgga	ggctatgact	agatactctg	8640
ccccccctgg	ggaccgccc	aaaccagaat	acgacttggg	gttgataaca	tcatgtcctt	8700
ccaatgtgtc	agtcgcgcac	gatgcactg	gcaaaagggt	gtactatctc	accctgacc	8760
ccaccacccc	ccttgccggg	gctgcgtggg	agacagctag	acacactcca	gtcaattcct	8820
ggctaggcaa	catcatcatg	tatgcgccca	ccttggtggc	aaggatgac	ctgatgactc	8880
atttcttctc	catccttcta	gctcaggaa	aaactgaaaa	agccctagat	tgtcagatct	8940
acggggcctg	ttacttcatt	gagccacttg	acctactcca	gatcattcaa	cgactccatg	9000
gccttagcgc	atcttctact	catagttact	ctccagggtg	gatcaatagg	gtggcttcat	9060

gcctcaggaa	acttggggta	ccgcccttgc	gagtcctggag	acatcggggc	agaagtgtcc	9120
gcgctaggct	actgtcccag	ggggggaggg	ctgccacttg	tggcaagtac	ctcttcaact	9180
gggcagtaag	gaccaagctc	aaactcactc	caatcccggc	tgcgtcccag	ttggatttat	9240
ccagctgggt	cgttgctggg	tacagcgggg	gagacatata	tcacagcctg	tctcgtgccc	9300
gaccccgtg	gttcatgtgg	tgccctactcc	tactttctgt	aggggtaggc	atctatctac	9360
tccccaaccg	atgaacgggg	agctaaacac	tccaggccaa	tagggcatcc	tgtttttttc	9420
cctttttttt	ttcttttttt	tttttttttt	tttttttttt	ttttttttct	cctttttttt	9480
tcctcttttt	ttccttttct	ttcctttggg	ggctccatct	tagccctagt	cacggctagc	9540
tgtgaaaggt	ccgtgagccg	cttgactgca	gagagtgtcg	atactggcct	ctctgcagat	9600
caagt						9605

<210> 3

<211> 10690

<212> DNA

<213> pHCVNeo.17 coding

<400> 3

gccagccccc	gattgggggc	gacactccac	catagatcac	tcccctgtga	ggaactactg	60
tcttcacgca	gaaagcgtct	agccatggcg	ttagtatgag	tgtcgtgcag	cctccaggac	120
ccccctcccc	gggagagcca	tagtgggtctg	cggaaaccgt	gagtacaccg	gaattgccag	180
gacgaccggg	tcctttcttg	gatcaaccgg	ctcaatgcct	ggagatttgg	gcgtgcccc	240
gcgagactgc	tagccgagta	gtgttggggtc	gcgaaaggcc	ttgtgggtact	gcctgatagg	300
gtgcttgcca	gtgccccggg	aggtctcgta	gaccgtgcac	catgagcacg	aatcctaatac	360
ctcaaagaaa	aaccaaaggg	cgcgccatga	ttgaacaaga	tggattgcac	gcaggttctc	420
cggccgcttg	ggtggagagg	ctattcggct	atgactgggc	acaacagaca	atcggctgct	480
ctgatgccgc	cgtgttccgg	ctgtcagcgc	aggggcgccc	ggttcttttt	gtcaagaccg	540
acctgtccgg	tgccctgaat	gaactgcagg	acgaggcagc	gcggctatcg	tggctggcca	600
cgacggggcg	tccttgccga	gctgtgctcg	acgttgtcac	tgaagcggga	agggactggc	660
tgctattggg	cgaagtgcgg	gggcaggatc	tcctgtcatc	tcaccttgct	cctgccgaga	720
aagtatccat	catggctgat	gcaatgcggc	ggctgcatac	gcttgatccg	gctacctgcc	780
cattcgacca	ccaagcga	catcgcatcg	agcgagcacg	tactcggatg	gaagccggtc	840
ttgtcgatca	ggatgatctg	gacgaagagc	atcaggggct	cgcgccagcc	gaactgttcg	900
ccaggctcaa	ggcgcgcatg	cccgacggcg	aggatctcgt	cgtgacccat	ggcgatgcct	960
gcttgccgaa	tatcatggtg	gaaaatggcc	gcttttctgg	attcatcgac	tgtggccggc	1020
tgggtgtggc	ggacgcgtat	caggacatag	cgttggttac	ccgtgatatt	gctgaagagc	1080
ttggcggcga	atgggctgac	cgttctctcg	tgttttacgg	tatcgccgct	cccgatctgc	1140
agcgcatcgc	cttctatcgc	cttcttgacg	agttcttctg	agtttaaaaca	gaccacaacg	1200
gtttccctct	agcgggatca	attccgcccc	tctccctccc	ccccccctaa	cgttactggc	1260
cgaagccgct	tggaataagg	ccggtgtgcg	tttgtctata	tgttattttc	caccatattg	1320
ccgtcttttg	gcaatgtgag	ggccccgaaa	cctggccctg	tcttcttgac	gagcattcct	1380
aggggtcttt	cccctctcgc	caaaggaatg	caaggtctgt	tgaatgtcgt	gaaggaagca	1440
gttctctctg	aagcttcttg	aagacaaaaca	acgtctgtag	cgaccctttg	caggcagcgg	1500
aaccccccac	ctggcgacag	gtgcctctgc	ggccaaaagc	cacgtgtata	agatacacct	1560
gcaaaggcgg	cacaacccca	gtgccacgtt	gtgagttgga	tagtttgtga	aagagtcaaa	1620
tggctctcct	caagcgtatt	caacaagggg	ctgaaggatg	cccagaaggt	accccatgtg	1680
atgggatctg	atctggggcc	tcgggtgcaca	tgttttacat	gtgttttagtc	gaggttaaaa	1740
aacgtctagg	ccccccgaac	cacggggacg	tgtttttcct	ttgaaaaaca	cgataataacc	1800
atggcgccca	ttacggccca	ctcccaacag	acgcgaggcc	tacttggctg	catcatcact	1860
agcctcacag	gccgggacag	gaaccaggtc	gagggggagg	tccaagtggg	ctccaccgca	1920
acacaatctt	tcctggcgac	ctgcgtcaat	ggcgtgtgtt	ggactgtcta	tcatgggtgc	1980
ggctcaaaga	cccttgccgg	cccaaaggcg	ccaatcaccc	aaatgtacac	caatgtggac	2040
caggacctcg	tcggctggca	agcgcccccc	ggggcgcggt	ccttgacacc	atgcacctgc	2100
ggcagctcgg	acctttactt	ggtcacagag	catgccgatg	tcattccggg	gcgcggcgcg	2160
ggcgacagca	gggggagcct	actctcccc	aggcccgctc	cctacttgaa	gggctcttcg	2220
ggcggtccac	tgtctgccc	ctcggggcac	gctgtgggca	tctttcgggc	tgcggtgtgc	2280
acccgagggg	ttgcgaaggc	ggtggacttt	gtaccgctcg	agtctatgga	aaccactatg	2340
cggctccccg	tcttcacgga	caactcgtcc	cctccggccg	taccgcagac	attccaggtg	2400
gcccattctac	acgcccctac	tggtagcggc	aagagcacta	aggtgcccgc	tgcgtatgca	2460
gcccgaagggt	ataagggtgt	tgtcctgaac	ccgtccgctg	ccgccaccct	aggtttcggg	2520
gcgtatatgt	ctaaggcaca	tggtatcgac	cctaaccatca	gaaccggggg	aaggaccatc	2580

accacgggtg	cccccatcac	gtactccacc	tatggcaagt	ttcttgccga	cgggtggttgc	2640
tctgggggcg	cctatgacat	cataatatgt	gatgagtgcc	actcaactga	ctcgaccact	2700
atcctgggca	tcggcacagt	cctggaccaa	gcggagacgg	ctggagcgcg	actcgtcgtg	2760
ctcgccaccg	ctacgcctcc	gggatcggtc	accgtgccac	atccaaacat	cgaggaggtg	2820
gctctgtcca	gcactggaga	aatccccctt	tatggcaaaag	ccatccccat	cgagaccatc	2880
aaggggggga	ggcacctcat	tttctgccat	tccaagaaga	aatgtgatga	gctcgcgcgg	2940
aagctgtccg	ggcctcgact	caatgctgta	gcatattacc	ggggccttga	tgtatccgtc	3000
ataccaacta	gcggagacgt	cattgtcgtg	gcaacggacg	ctctaatac	gggctttacc	3060
ggcgatttgc	actcagtgat	cgactgcaat	acatgtgtca	cccagacagt	cgacttcagc	3120
ctggaccgga	ccttcaccat	tgagacgacg	accgtgccac	aagacgcggg	gtcacgctcg	3180
cagcgccgag	gcaggactgg	taggggcagg	atgggcattt	acaggtttgt	gactccagga	3240
gaacggccct	cgggcatggt	cgattcctcg	gttctgtgcg	agtgtatga	cgcgggctgt	3300
gcttggtacg	agctcacgcc	cgccgagacc	tcagttaggt	tgcgggctta	cctaaacaca	3360
ccagggttgc	ccgtctgcca	ggaccatctg	gagttctggg	agagcgtctt	tacaggcctc	3420
cacgacatag	acgcccattt	cttgtcccag	caggaacagg	caggagacaa	cttcccctac	3480
ctggtagcat	accaggctac	ggtgtgcgcg	agggtcagg	ctccacctcc	atcgtgggac	3540
caaagtgtga	agtgtctcat	acggctaaag	cctacgctgc	acgggccaac	gcccctgctg	3600
tataggctgg	gagccgttca	aaacgaggtt	actaccacac	accccataac	caaatacatc	3660
atggcagca	tgctggctga	cctggaggtc	gtcacagaca	cctgggtgct	ggtaggcgga	3720
gtcctagcag	gtctggccgc	gtattgcctg	acaacaggca	gcgtggctcat	tgtgggcagg	3780
atcatcttgt	ccggaagacc	ggccatcatt	ccgcacaggg	aagtccttta	ccgggagttc	3840
gatgagatgg	aagagtgcgc	ctcacacctc	ccttacatcg	aacagggaat	gcagctcgcc	3900
gaacaattca	aacagaaggc	aatcgggttg	ctgcaaacag	ccaccaagca	agcggaggct	3960
gctgctcccg	tggtggaatc	caagtggcgg	accctcgaa	ccttctgggc	gaagcatatg	4020
tggaatttca	tcagcgggat	acaatattta	gcaggcttgt	ccactctgcc	tggcaacccc	4080
gcgatagcat	cactgatggc	attcacagcc	tctatcacca	gcccgtctac	cacccaacat	4140
accctcctgt	ttaacatcct	ggggggatgg	gtggccgccc	aacttgctcc	tcccagcgct	4200
gcttctgctt	tcgtaggcgc	cgccatcgct	cgccatcgct	ttggcagcat	aggccttggg	4260
aagggtgctt	tggaattttt	ggcaggttat	ggagcagggg	tggcagggcg	gctcgtggcc	4320
tttaaggtca	tgagcggcga	gatgccctcc	accgaggacc	tggttaacct	actccctgct	4380
atcctctccc	ctggcgccct	agtcgtcggg	gtcgtgtgcg	cagcgatact	gcgtcggcac	4440
gtggctcccg	tcgtaggggc	tgtgcagtgg	atgaaccggc	tgatagcggt	cgcttcgcgg	4500
ggtaaccacg	tctcccccc	gcactatgtg	cctgagagcg	acgctgcagc	acgtgtcact	4560
cagatcctct	ctagtcttac	catcactcag	ctgctgaaga	ggcttcacca	gtggatcaac	4620
gaggactgct	ccacgccatg	ctccggctcg	tggctaagag	atgtttggga	ttggatatgc	4680
acggtgttga	cgattttcaa	gacctggctc	atgaaccagg	tcctgcccgc	attgcccggg	4740
gtccccctct	tctcatgtca	acgtgggtac	aagggaagtct	ggcgggggcg	cgccatcatg	4800
caaaccacct	gcccattgtg	agcacagatc	accggacatg	tgaaaaacgg	ttccatgagg	4860
atcgtggggc	ctaggacctg	tagtaaacg	tggcatggaa	cattccccat	taacgcgtac	4920
accacggggc	cctgcacgcc	ctccccggcg	ccgaattatt	ctagggcgct	gtggcgggtg	4980
gctgctgagg	agtacgtgga	ggttacgcgg	gtgggggatt	tccactacgt	gacgggcatg	5040
accactgaca	acgtaaagtg	cccgtgtcag	gttccggccc	ccgaattctt	cacagaagtg	5100
gatgggggtg	ggttgcacag	gtacgtcca	gcgtgcaaac	ccctcctacg	ggaggaggtc	5160
acattcctcg	tcgggctcaa	tcaatacctg	gttgggtcac	agctcccatg	cgagcccga	5220
ccggacgtag	cagtgctcac	ttccatgctc	accgaccctc	cccacattac	ggcggagacg	5280
gctaagcgta	ggctggccag	gggatctccc	ccctccttgg	ccagctcatc	agctagccag	5340
ctgtctgcgc	cttctttgaa	ggcaacatgc	actaccgctc	atgactcccc	ggacgctgac	5400
ctcatcgagg	ccaacctcct	gtggcggcag	gagatgggcg	ggaacatcac	ccgcgtggag	5460
tcagaaaata	aggtagtaat	tttggactct	ttcgagccgc	tccaagcgga	ggaggatgag	5520
agggaagtat	ccgttccggc	ggagatcctg	cggaggtcca	ggaaattccc	tcgagcgatg	5580
cccataatgg	cacgcccggg	ttacaaccct	ccactgttag	agtcctggaa	ggacccggac	5640
tacgtccctc	cagtgggtaca	cgggtgtcca	ttgcccgcct	ccaaggcccc	tccgatacca	5700
cctccacgga	ggaagaggac	ggttgtcctg	tcagaattcta	ccgtgtcttc	tgccttggcg	5760
gagctcgcca	caaagacctt	cggcagctcc	gaatcgctcg	ccgtcgacag	cggcacggca	5820
acggccctct	ctgaccagcc	ctccgacgac	ggcgacgcgg	gatccgacgt	tgagtcgtac	5880
tcctccatgc	cccccttga	gggggagccg	ggggatcccc	atctcagcga	cgggtcttgg	5940
tctaccgtaa	gcgtgaggac	tagtgaggac	gtctctgtcg	gctcgatgtc	ctacacatgg	6000
acaggcgccc	tgatcacgcc	atgcgctgcg	gaggaaacca	agctgcccac	caatgcactg	6060
agcaactctt	tgctccgtca	ccacaacttg	gtctatgcta	caacatctcg	cagcgcaagc	6120
ctgcccagga	agaaggtcac	ctttgacaga	ctgcaggctc	tggacgacca	ctaccgggac	6180
gtgctcaagg	agatgaaggc	gaaggcgtcc	acagttaagg	ctaaacttct	atccgtggag	6240
gaagcctgta	agctgacgcc	cccacattcg	gccagatcta	aatttggcta	tggggcaaa	6300

gacgtccgga	acctatccag	caaggccggt	aaccacatcc	gctccgtgtg	gaaggacttg	6360
ctggaagaca	ctgagacacc	aattgacacc	accatcatgg	caaaaaatga	ggttttctgc	6420
gtccaaccag	agaagggggg	ccgcaagcca	gctcgcccta	tcgtattccc	agatttgagg	6480
gttcgtgtgt	gcgagaaaat	ggccctttac	gatgtgggtc	ccaccctccc	tcaggccgtg	6540
atgggctctt	catacggatt	ccaatactct	cctggacagc	gggtcagagt	cctgggtgaat	6600
gcctggaaa	cgaagaaatg	ccctatgggc	ttcgcatatg	acaccgctg	ttttgactca	6660
acggctactg	agaatgacat	ccgtgttgag	gagtcaatct	accaatgttg	tgacttggcc	6720
cccgaagcca	gacaggccat	aaggctcgctc	acagagcggc	tttacatcgg	gggccccctg	6780
actaatctta	aagggcagaa	ctgcggctat	cgccgggtgcc	gcgcgagcgg	tgtactgacg	6840
accagctcgg	gtaataccct	cacatgtttac	ttgaaggccg	ctgcggcctg	tcgagctgcg	6900
aagctccagg	actgcacgat	gctcgatatg	ggagacgacc	ttgtcgttat	ctgtgaaagc	6960
gcggggaccc	aagaggacga	ggcgagccta	cgggccttca	cggaggctat	gactagatac	7020
tctgcccccc	ctggggaccc	gccccaaacca	gaatacgaact	tggagtgtgat	aacatcatgc	7080
tcttccaatg	tgtcagtcgc	gcacgatgca	tctggcaaaa	gggtgtacta	tctcaccctg	7140
gacccccacca	ccccccttgc	gcgggtcgcg	tgcagagacag	ctagacacac	tccagtcagt	7200
tcttggttag	gcaacatcat	catgtatgcg	cccaccttgt	gggcaaggat	gactcctgatg	7260
actcatttct	tctccatcct	tctagctcag	gaacaacttg	aaaaagccct	agattgtcag	7320
atctacgggg	cctgttactc	cattgagcca	cttgaccta	ctcagatcat	tcaacgactc	7380
catgccccta	gcgcattttt	actccatagt	tactctccag	gtgagatcaa	taggggtggct	7440
tcatgcctca	ggaaacttgg	ggtaccgccc	ttgcgagtct	ggagacatcg	ggccagaagt	7500
gtccgcgcta	ggctactgtc	ccaggggggg	agggctgcc	cttgtggcaa	gtacctcttc	7560
aactgggag	taaggacca	gctcaaatc	actccaatcc	cggctgcgct	ccagtgtggat	7620
tatatccagct	ggttcgttgc	tggttacagc	gggggagaca	tatatcacag	cctgtctcgt	7680
gccccacccc	ctgtggtcat	gtggtgccta	ctctactttt	ctgtaggggt	aggcatctat	7740
ctactcccca	accgatgaac	ggggagctaa	acactccagg	ccaataggcc	atcctgtttt	7800
tttccctttt	tttttttctt	tttttttttt	tttttttttt	tttttttttt	ttctcctttt	7860
tttttctctt	ttttttcctt	ttcttttctt	tggtggctcc	atcttagccc	tagtcacggc	7920
tagctgtgaa	aggctcgtga	gccgcttgac	tgcagagagt	gctgatactg	gcctctctgc	7980
agatcaagta	cttctagaga	attctagctt	ggcgtaata	tggtcatagc	tgtttctctg	8040
gtgaaattgt	tatcagctca	caattccaca	caacatacga	gccggaagca	taaagtgtaa	8100
agcctgggat	gcctaattag	tgagctaact	cacattagtt	gcgttgcgct	cactgcccgc	8160
tttccagctg	ggaaacctgt	ctgtccagct	ccattagtga	atcgctccaac	gcacggggag	8220
aggcggtttg	cgtattgggc	gcacttccgc	ttctctcgct	actgactcgc	tgcgctcgtt	8280
cgttcggctg	cggcgagccg	tatcagctca	ctcaaaggcg	gtaatacgg	tatccacaga	8340
atcaggggat	aacgcaggaa	agaccatgtg	agcaaaaagg	cagcaaaaagg	ccaggaaccg	8400
taaaaaggcc	cgtttgctgg	ggtttttcca	taggctccgc	ccccctgacg	agcatcacaa	8460
aaatcgacgc	tcaagtcaga	ggtggcgaaa	ccgcagagga	ctataaagat	accaggcggt	8520
tccccctgga	agctccctcg	tgcgctctcc	tggtccgacc	ctgccgctta	ccggatacct	8580
gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcat	agctcacgct	gtaggatatc	8640
cagttcgggt	tagtctggtc	gtcccaagct	gggtgtgtg	cacgaacccc	ccgttcagcc	8700
cgaccgctgc	gccttatccg	gtaactatcg	tcttgatccc	aaccgggtaa	gacacgactt	8760
atcgccactg	gcagcagcca	ctggtaacag	gattagcaga	gcgagggtatg	taggcgggtgc	8820
tacagagttc	ttgaagtgg	ggcctaacta	cggctacact	agaaggacag	tatttgggtat	8880
ctgcgctcgc	ctgaagccag	ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	8940
acaaaaccac	gctggtagcg	gtgggttttt	tgtttgcaag	cagcagatta	cgcgagaaa	9000
aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	tctgacgctc	agtggaaacga	9060
aaactcacgt	taagggat	tggtcatgag	attatcaaaa	aggatcttca	cctagatcct	9120
tttaaattaa	aaatgaagtt	ttaaatcaat	ctaaagtata	tatgagtaaa	cttgggtctga	9180
cagttaccaa	tgcttaata	gtgaggcacc	tatctcagcg	atctgtctat	ttcgttctac	9240
catagttgcc	tgactccccg	tcgtgtagat	aactacgata	cgggagggct	taccatctgg	9300
ccccagtgct	gcaatgatac	cgcgagaacc	acgctcacc	gcaccagatt	tatcagcaat	9360
aaaccagcca	gccggaagtg	cgctgcggag	aagtggctct	gcaactttat	ccgcctccat	9420
ccagtcattt	agttgttgcc	gggaagctag	agtaagtagt	tcgccagtca	gcagtttgcg	9480
taacgtcggt	gccatagcaa	caggcatcgt	ggtgtcacgc	tcgtcgtttg	gtatggcttc	9540
attcagctcc	ggctcccaac	gatcaaggcg	agttacatga	tcccccatgt	tgtgcaaaaa	9600
agcgggttagc	tccttcgggtc	ctccgatcgt	tgtcagaagt	aagttggccg	cagtggttatc	9660
actcatgggt	atggcagcac	tgcataatct	atgctatgct	atgcccctcg	taagatgctt	9720
ttctgtgact	ggtgagtact	caaccaagtc	attctgagaa	tagtgtatgc	ggcgaccgag	9780
ttgtctttgc	ccggcgtaaa	tacgggataa	taccgcgcca	catagcagaa	ctttaaaagt	9840
gctcatcatt	ggaaaacggt	cttcggggcg	aaaactctca	aggatcttac	cgctgttgag	9900
atccagttcg	atgtaaccca	ctcgtgcacc	caactgatct	tcagcatctt	ttactttcac	9960
cagcgtttct	gggtgagcaa	aaacaggaag	gcaaaatgcc	gcaaaaaagg	gaataagggc	10020

gacacggaaa	tgttgaatac	tcatactctt	cctttttcaa	tattattgaa	gcatttatca	10080
gggttattgt	ctcatgagcg	gatacatatt	tgaatgtatt	tagaaaaata	aacaaatagg	10140
ggttccgcgc	acatttcccc	gaaaagtgcc	acctgacgtc	taagaaacca	ttattaccat	10200
gacattaacc	tataaaaaata	ggcgtatcac	gaagcccttt	cgtctagcgc	gtttcgggtga	10260
tgacgggtgaa	aacctctgac	acttgcagct	cccgcagacg	gtcacagctt	gtctgtaagc	10320
ggatgccggg	agcaggcaag	cccgtcaggg	cgcgtcagtg	gggtgttggcg	gggtgtcgggg	10380
ctggcttaac	tatgcggcat	cagagcagat	tgtactgaga	gtacaccaga	tgcggtgtga	10440
aataccgcac	agatgcgtaa	ggagaaaata	ccgcatacag	ctccattcgc	cattcagact	10500
ccgcaactgt	tgggaagggc	ggtcagtacg	cgcttcttcg	ctattacgcc	aactggcgaa	10560
agggggatgt	gctgcaaggc	gattaagttg	ggtaacgcca	gggttttccc	aatcacgacg	10620
ttgtaaaacg	acagccaatg	aattgaagct	tattaattct	agactgaagc	ttttaatacg	10680
actcactata						10690

<210> 4

<211> 23

<212> DNA

<213> Primer oligonucleotide

<400> 4

acatgatctg cagagaggcc agt

23

<210> 5

<211> 26

<212> DNA

<213> Primer oligonucleotide

<400> 5

gacasgctgt gatawatgtc tcccc

26

<210> 6

<211> 21

<212> DNA

<213> Primer oligonucleotide

<400> 6

tggctctcct caagcgtatt c

21

<210> 7

<211> 23

<212> DNA

<213> Primer oligonucleotide

<400> 7

actctctgca gtcaagcggc tca

23

<210> 8

<211> 21

<212> DNA

<213> Primer oligonucleotide

<400> 8

cagtggatga accggctgat a

21

<210> 9

<211> 23

<212> DNA

<213> Primer oligonucleotide

<400> 9

ggggcgacgg catcatgcaa acc

23

<210> 10
<211> 23
<212> DNA
<213> Primer oligonucleotide

<400> 10
caggacctgc agtctgtcaa agg 23

<210> 11
<211> 17
<212> DNA
<213> Primer oligonucleotide

<400> 11
cgggagagcc atagtgg 17

<210> 12
<211> 19
<212> DNA
<213> Primer oligonucleotide

<400> 12
agtaccacaa ggcctttcg 19

<210> 13
<211> 21
<212> DNA
<213> Probe

<400> 13
ctgcggaacc ggtgagtaca c 21

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 2002/059321 A3

(51) International Patent Classification⁷: **C12N 15/40**,
15/51, 5/10, C07K 14/18, C12N 15/85, 7/00, G01N 33/50

(IT). PAONESSA, Giacomo [IT/IT]; IRBM, Via Pontina
Km. 30, 600, I-00040 Pomezia (Rome) (IT).

(21) International Application Number:
PCT/EP2002/000526

(74) Agent: THOMPSON, John; Merck & Co., Inc., European
Patent Department, Terlings Park, Eastwick Road, Harlow,
Essex CM20 2QR (GB).

(22) International Filing Date: 16 January 2002 (16.01.2002)

(81) Designated States (*national*): CA, JP, US.

(25) Filing Language: English

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(26) Publication Language: English

(30) Priority Data:
60/263,479 23 January 2001 (23.01.2001) US

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(71) Applicant (*for all designated States except US*): ISTI-
TUTO DI RICERCHE DI BIOLOGIA MOLECO-
LARE P. ANGELETTI SPA [IT/IT]; Via Pontina Km.
30, 600, I-00040 Pomezia (Rome) (IT).

(88) Date of publication of the international search report:
25 March 2004

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DE FRANCESCO,
Raffaele [IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040
Pomezia (Rome) (IT). MIGLIACCIO, Giovanni [IT/IT];
IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia (Rome)

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 2002/059321 A3

(54) Title: HEPATITIS C VIRUS REPLICONS AND REPLICON ENHANCED CELLS

(57) Abstract: The present invention features nucleic acid containing one or more adaptive mutations, and HCV replicon enhanced cells. Adaptive mutations are mutations that enhance HCV replicon activity. HCV replicon enhanced cells are cells having an increased ability to maintain an HCV replicon.